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ABSTRACT
Background. Studies have shown contradictory results with regard to the
severity and extent of coronary artery disease (CAD) in the diabetic popu-
lation. Despite this, common clinical opinion suggests that diabetic
patients with coronary artery disease (CAD) have an extensive and dif-
fuse type of disease affecting particularly the distal parts of the coronary
vessels. This view may raise the threshold for invasive examinations and
worsen possibilities for early detection of CAD. However, early enough
treatment of CAD with coronary artery bypass surgery or with percuta-
neous coronary interventions is extremely important for diabetic patients
who are at high risk for adverse outcome or even death after their first
acute coronary event such as myocardial infarction. 
Aims. The present studies were undertaken to discover whether a) the
angiographic severity and extent of CAD differ quantitatively between type
2 diabetic and nondiabetic, and type 1 diabetic and nondiabetic patients
undergoing clinically indicated coronary angiography, and b) to investigate
risk factors that may be related to the anatomical distribution of CAD in
diabetic patients and in subjects from high-risk families. 
Subjects. The study population in Studies I and II comprised 57 consecu-
tive type 2 diabetic patients undergoing clinically indicated elective coro-
nary angiography at Helsinki University Central Hospital between Septem-
ber 1989 and February 1992. Each patient had type 2 diabetes fulfilling
the World Health Organization 1980 criteria and, by coronary angiogram,
at least one > 50% severe stenosis. A corresponding number of nondia-
betic CAD patients were individually matched with type 2 diabetes
patients by sex, age, and body mass index. Study III comprised 46 men in
the diabetic and 42 men in the nondiabetic group. For Study IV, patients
with type 1 diabetes who underwent cardiac catheterization for symptoms
of CAD at the Helsinki University Central Hospital between 1982 and
1997 were identified. All the 72 patients had previously diagnosed dia-
betes fulfilling the World Health Organization 1980 criteria for type 1 dia-
betes mellitus. Nondiabetic controls from the same population were
matched individually with the diabetic patients for sex, age, date of
angiography, and serum creatinine value. Study V comprised 51 asympto-
matic members of high-risk families identified at Kuopio University Hospi-
tal that were siblings of patients with premature severe CAD. 
Methods. Third-generation quantitative coronary angiography software
were used in the analysis of coronary angiograms. We created a novel
computer-assisted quantitative coronary angiography-based scoring
system for evaluation of the severity and extent of CAD. These indices of
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severity, extent, and atheroma burden provide a specific per-patient esti-
mate of the total atheroma burden of the coronary tree and make possi-
ble accurate subsegmental analyses. Associations between these novel
indices of CAD and a) clinical data, b) potential risk factors, and c) the
capacity of plasma to induce cholesterol efflux were studied by use of
univariate correlation analyses and multivariate regression models. 
Results and conclusions. To our knowledge, this is the first study to use
quantitative coronary angiography-based estimates to quantify the sever-
ity and extent of CAD. Type 1 diabetic subjects, particularly women, had
more severe and extensive CAD than did nondiabetic patients. The
greater impact of diabetes on diabetic women is not explained by the
known risk factors. The severity and extent of CAD in type 2 diabetic
patients and in matched nondiabetic subjects were similar. Our results
are, however, limited to patients that became symptomatic and needed
angiographic assessment at similar ages. Further research is needed to
evaluate the severity and extent of CAD in type 2 diabetic women. The
severity of CAD was associated with ”traditional” risk factors in nondia-
betic control subjects and with diabetes-related variables in type 2 dia-
betic patients. Even normal levels of apolipoprotein B-containing particles
are atherogenic when diabetes is present. In vitro cholesterol efflux
capacity was inversely associated with severity and extent of CAD in men
with type 2 diabetes and in nondiabetic subjects. In the diabetic group,
the fact that this association was independent of LpA-I levels suggests
that in type 2 diabetic patients with CAD, the antiatherogenic potential of
LpA-I particles is diminished. In high-risk subjects, serum homocysteine
and glucose levels were associated with severity and extent of CAD. 
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ABBREVIATIONS
ABCA1 ATP-binding cassette transporter 1
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EBCT electron-beam computed tomography
FFA free fatty acid
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IDDM insulin-dependent diabetes mellitus
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QCA quantitative coronary angiography
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1. INTRODUCTION
Diabetes mellitus affects about 3 to 5% of the population in the devel-
oped countries (Laakso 2000). It is associated with several complications
that impair quality of life (Hänninen et al. 1998) as well as causing a huge
economic burden on society (Olsson et al. 1994). Cardiovascular diseases
are the major cause of death among patients with both main types of dia-
betes, 1 and 2 (Kannel and McGee 1979b, Steiner 1985, Kleinman et al.
1988, Morrish et al. 2001). Large epidemiological studies such as the
Framingham study have identified diabetes mellitus as one of the most
important independent risk factors for coronary artery disease (CAD)★
(Kannel and McGee 1979b).
Mortality due to CAD has declined by 60% during the past 20 years in
eastern Finland in the population < 65 years (Salomaa et al. 1996), and
similar declining trends have been reported from the United States in the
adult population < 75 years (Gu et al. 1999). Unfortunately, this positive
tendency in CAD mortality in the nondiabetic population does not apply to
the diabetic cohort. In the USA during the past 30 years, nondiabetic men
experienced a 44% decline in age-adjusted mortality due to CAD com-
pared to only 17% in diabetic men. During the same period, mortality in
nondiabetic women fell 20%, but simultaneously increased 11% in dia-
betic women (Gu et al. 1999).
Despite overall decreasing numbers of CAD cases, the population diag-
nosed with diabetes mellitus seems to be increasing rapidly (King et al.
1998, Zimmet et al. 2001). The global number of people with diabetes is
estimated to rise by 2025 from the current 150 million to 300 million
(Zimmet et al. 2001). In Finland, the incidence of type 1 diabetes (insulin-
dependent) in children ≤ 14 years is reported to be the highest in the
world (EURODIAB ACE Study Group 2000). The current prevalence of type
1 diabetes in Finland is  40 000 (0.8%), and, at the moment, 3% (156
500) of the Finnish population has been diagnosed with type 2 diabetes
(non-insulin-dependent) (Antti Reunanen, personal communication,
unpublished data). This number would, however, be at least 30% higher if
asymptomatic nondiagnosed subjects with a blood glucose concentration
exeeding the criterion for diabetes were counted (Antti Reunanen, per-
sonal communication, unpublished data). 
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★For consistency, the term ”coronary artery disease” (CAD) is used throughout the text of this sum-
mary. However, if strictly defined, this term should be used only when diagnosis is based on coronary
angiography or autopsy. The terms ”ischemic heart disease” or ”coronary heart disease” was origi-
nally used in some of the cited articles. Some authors use ”coronary heart disease” also to cover
CAD-related clinical events such as angina pectoris, MI, and sudden cardiac death.
Even though the increased risk for CAD in the diabetic population is well
recognized (Zimmet et al. 2001), less data exist as to the factors that
determine the severity and extent of CAD and its anatomical distribution
in the coronary tree in different patient populations. The severity and
extent of CAD in diabetic patients compared with figures for nondiabetic
subjects is controversial, although some data do suggest a more diffuse
and distally located coronary atherosclerosis in diabetic patients, as dis-
cussed in more detail in section 2.5. (Jacoby and Nesto 1992, American
Diabetes Association 1997). 
The idea of a diffuse and distal type of CAD may reduce the number of
diabetic patients to whom invasive diagnostic tools such as angiography
are offered. This may mean that diabetic subjects may receive a coronary
artery bypass surgery or percutaneous transluminal coronary angioplasty
and other types of percutaneous coronary interventions less often than
do nondiabetic CAD patients. These treatment methods are used to treat
symptoms of CAD and in some patient populations are shown to improve
prognosis and prevent deaths. Though outcome after these interventions
is worse in diabetic than in nondiabetic patients (Morris et al. 1991,
Halon et al. 1998, Weintraub et al. 1998), such interventions are
extremely important for diabetic patients who are at high risk for adverse
outcome or even death after an acute coronary event such as unstable
angina (Malmberg et al. 2000) or myocardial infarction (MI), even when
treated with thrombolytic agents (Woodfield et al. 1996, Mak et al. 1997). 
More precise knowledge of the severity and extent of CAD in different sub-
types of diabetes may reduce the threshold for invasive examinations and
improve possibilities for early detection of CAD.
★
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2. REVIEW OF THE LITERATURE
2.1. DIABETES MELLITUS
2.1.1. Classification and nomenclature
According to the definition of the American Diabetes Association (ADA) in
1997, ”diabetes mellitus is a group of metabolic diseases characterized
by hyperglycemia resulting from defects in insulin secretion, insulin
action, or both.”
The old World Health Organization (WHO) Expert Committee classifica-
tions of diabetes were based on treatment needed rather than on etiology
(WHO Expert Committee on Diabetes Mellitus 1965, 1980 and 1985). An
Expert Committee, sponsored by the ADA, was established in 1995 to
revise the older classifications (ADA 1997). For the same reasons, the
WHO established a ”consultation” in 1996; however, the 1999 document
is not a formal publication of the WHO (WHO 1999). Nevertheless, the
ADA and WHO groups reached mostly similar conclusions. 
In these new etiology-based criteria for diabetes mellitus, the diagnostic
fasting plasma glucose was lowered from 7.8 mmol/l to 7.0 mmol/l (WHO
1985), and a new category, impaired fasting glycemia (IFG) was intro-
duced (ADA 1997). The diagnostic 2-hour glucose concentrations for dia-
betes and for impaired glucose tolerance (IGT) remained unchanged (ADA
1997). The committee also suggested the terms ”IDDM” (insulin-depend-
ent diabetes mellitus) and ”NIDDM” (noninsulin-dependent diabetes mel-
litus) be replaced with the terms ”type 1” and ”type 2” diabetes and, in
addition, classified diabetes mellitus into four main etiologic classes: 1)
type 1 diabetes, 2) type 2 diabetes, 3) other specific types (including vari-
ous subtypes such as ”MODY 1 to 4” and types that are classified into
”genetic defects of β-cell function”), and 4) gestational diabetes mellitus
(ADA 1997). 
The ADA Expert Committee (1997) gives primacy to the fasting plasma
glucose in clinical diagnosis of diabetes in contrast to the WHO 1999
consultation document that suggests the use of both the 2-hour and the
fasting values. This ADA criterion has not been accepted without criticism.
It has been claimed that if fasting glucose alone is used, around 30% of
diabetic subjects with a non-diabetic fasting glucose but a diabetic 2-hour
glucose value will not be properly diagnosed (The DECODE-study group
1999a and 1999b). 
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2.1.2. Type 1 (insulin-dependent)
”Type 1 diabetes mellitus is an immune-mediated disease that normally
occurs in chidhood or adolecence but may occur at any age” (ADA 1997).
It results from an autoimmune destruction of pancreatic β-cells (Atkinson
and Maclaren 1994) that may proceed quickly in infants and children, or
proceed slowly usually in adults (Zimmet et al. 1994). 
2.1.3. Type 2 (noninsulin-dependent)
Type 2 diabetes is the most prevalent form of diabetes, and its exact eti-
ologies, probably several, are still unknown. No autoimmune destruction
of pancreatic β-cells can be seen in type 2 diabetes, and the gradual
development of the disease keeps it undiagnosed usually for years. In
type 2 diabetic patients, diabetic status ranges from predominantly
insulin resistance with relative insulin deficiency to predominantly an
insulin secretory defect with insulin resistance (ADA 1997). Age and obe-
sity increase the incidence of type 2 diabetes that is associated with
strong genetic links (Newman et al. 1987). 
2.1.4. ”Diabetes is a vascular disease”
Among both type 1 and type 2 patients, cardiovascular diseases, includ-
ing CAD, stroke, and peripheral vascular disease, are the most important
cause of mortality and morbidity (Kannel and McGee 1979b, Steiner
1985, Kleinman et al. 1988).
Diabetic patients are at high risk for MI, and have a high mortality rate
even after their first MI (Miettinen et al. 1998). In that study based on the
FINMONICA register, the 1-year mortality rate was 44% in diabetic men,
33% in nondiabetic men, 37% in diabetic women, and 20% in nondia-
betic women. Indeed, the risk for the first MI in patients with type 2 dia-
betes is identical to that of those nondiabetic patients who already have
suffered one (Haffner et al. 1998). This important finding was confirmed
by the prospective Organization to Assess Strategies for Ischemic Syn-
dromes study, showing similar results in 8 013 patients (21% with dia-
betes) who were hospitalized with unstable angina or non-Q-wave MI
(Malmberg et al. 2000). In that study, during a 2-year follow-up, diabetic
patients without previous CAD diagnoses had the same future mortality
as did nondiabetic patients with established CAD after a new event. Fur-
thermore, in a prospective cohort study of 1 935 patients hospitalized
with a confirmed acute MI, the magnitude of the effect of diabetes was
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identical to that of a previous MI during a mean follow-up of 3.7 years
(Mukamal et al. 2001).
As reviewed by Mukamal et al. (2001), the presence of diabetes is associ-
ated with nearly 2-fold higher long-term mortality after MI, even after
adjustment for confounding factors. Although diabetic subjects have a
higher prevalence of traditional coronary heart disease risk factors such
as hypertension, dyslipidemia, and obesity than do individuals without
diabetes, these risk factors account for less than half of the excess mor-
tality related to diabetes (Stamler et al. 1993). Other diabetes-related fac-
tors such as impaired left ventricular function, autonomic neuropathy,
endothelial dysfunction, and enhanced thrombus formation also con-
tribute to the increased risk (Jacoby and Nesto 1992). 
2.2. SIGNIFICANCE OF SEVERITY AND EXTENT OF CORONARY
ARTERY DISEASE
Stenosis severity and number of vessels with atheromatous lesions indi-
cate future cardiac morbidity and mortality (Moise et al. 1984). However,
plaques of only mild or moderate severity are frequently those that
undergo the disruption finally causing an unstable anginal attack or MI
(Davies and Thomas 1985, Fuster et al. 1990). Little et al. (1988) showed
that the severity of a stenosis causing an infarction was < 50% in two-
thirds of the MI patients, and the most severe lesion was responsible for
the MI in only one-third of the patients. Accordingly, it has been demon-
strated that the artery that occludes during an acute MI generally has a
< 75% stenosis, and diabetic patients are reported to have such stenoses
more often than do nondiabetic patients (Henry et al. 1997).
Stenosis descriptors other than severity may better predict future coro-
nary events. Among other lesion-specific factors, the morphological and
histologic type of stenosis predicts onset of unstable angina (Ambrose et
al. 1985). Ledru et al. (1999) used computer-assisted quantification of
coronary angiograms to study the relation between characterization of
stenosis geometry and risk for MI. The severity of the stenosis predicted
only infarctions occurring within one year after angiography, while sym-
metry index and outflow angles accurately predicted lesions that
remained free of occlusion and infarction during a 3-year follow-up. Exten-
sive and diffuse CAD may be more harmful than less extensive but more
severe disease. Diabetic patients have a higher incidence of plaque ulcer-
ation and more complex morphology of the atherosclerotic lesions that
may be related to their higher risk of acute coronary events (Silva et al.
1995).
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2.3. ATHEROSCLEROSIS IS A MULTIFACTORIAL DISEASE
2.3.1. Overview 
Lipid abnormalities, diabetes, hypertension, male gender, cigarette smok-
ing and genetic predisposition are well-known ”classic” risk factors for
CAD (Kannel et al. 1979, Kannel and McGee 1979a, Hasin et al. 1979,
Wilson et al. 1999a). Epidemiological evidence suggests that these clas-
sic risk factors explain approximately two-thirds of the variation in the
anatomic extent of CAD (Eikelboom et al. 1999). New emerging risk fac-
tors, such as factors related to hemostatic function (Koenig 1998), hyper-
homocysteinemia (Eikelboom et al. 1999, Glenn and Duell 1999), insulin
resistance and/or hyperinsulinemia (Spallarossa et al. 1994, Meigs et al.
2000, Kuusisto et al. 2001), and microalbuminuria (Yudkin et al. 1988,
Kuusisto et al. 1995, Gerstein et al. 2001) have been related to increased
risk for CAD. Inflammation plays a pivotal role in several stages of athero-
genesis, and markers of the inflammatory process such as C-reactive pro-
tein are shown to be associated with CAD and related coronary events
(Liuzzo et al. 1994, Ross 1999, Torzewski et al. 2000). Common infec-
tions caused by Chlamydia pneumoniae, and viruses such as those of
the cytomegalo and herpes species are linked to development of athero-
sclerosis (Saikku et al. 1988, Epstein et al. 1999, Hu et al. 1999, Muh-
lestein et al. 2000). Studies on young trauma victims without symptoms
of CAD have shown that, even at the very early stages of the atheroscle-
rotic process, number of risk factors predicts amount of atheroma in coro-
nary vessels (Berenson et al. 1998). 
2.3.2. Development of an atheromatous plaque
Atherosclerosis occurs in arteries mainly at so-called lesion-prone sites
near the vessel branches and bifurcations at which local factors such as
variable blood flow influence the atherogenic process (Gotto and Pownall
1999a). Previously, atherosclerosis was considered a fairly steadily pro-
gressive process with continuous accumulation of atherogenic compo-
nents into the vessel wall. Today this view has radically changed, because
of discovery of the complexity of the mechanisms behind the atherogenic
process (Kruth 1997, Gotto and Pownall 1999a). The exact mechanism of
atherosclerosis is still unknown, however, and a major question remains
unanswered: what initiates the atherosclerotic process?
In coronary arteries, fatty streaks represent the earliest forms of athero-
sclerotic lesions (Stary 1989). Fatty streaks are composed of macrophage
foam cells, smooth muscle cells, and extracellular lipids, and they turn
into fibroatheromas through accumulation of more extracellular lipid and
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proliferation of the smooth muscle cells (Stary 1989). Macrophages play
important roles in the development of CAD by contributing to the uptake
of lipids, taking part in the oxidation of low-density lipoprotein (LDL), and
releasing proteases (Mitchinson and Ball 1987). The chronic inflamma-
tory state (Ross 1999) may finally lead to acute clinical plaque rupture
and thrombosis resulting in MI (Fuster et al. 1992a and 1992b). Plaques
prone to rupture are lipid-rich, containing high a concentration of choles-
terol and its esters (Davies and Thomas 1985). High-grade coronary
stenosis can result from sudden plaque growth following subclinical
episodes of plaque disruption and healing. This may explain the phasic
development of coronary plaque (Mann and Davies 1999). 
2.3.3. Lipid metabolism 
As shown in Table 1, plasma lipoproteins are complexes composed of
apolipoproteins and lipids. The structure and composition of lipoproteins
vary, and they are classified based on their densities and electrophoretic
mobilities (Gotto and Pownall 1999b). 
Table 1. Plasma lipoproteins in decending order according to density
Lipoprotein Major lipid Major apolipoprotein 
component(s) component(s)
Chylomicrons triglyceride A-I, A-II, A-IV, B-48,C-I, C-II, C-III, E
Chylomicron cholesteryl ester, triglyceride B-48, E
remnants
VLDL triglyceride B-100, C-I, C-II, C-III, E
IDL cholesteryl ester B-100, C-I, C-II, C-III, E
LDL cholesteryl ester B-100
HDL2 cholesteryl ester, phospholipid A-I, A-II
HDL3 phospholipid A-I, A-II
Table modified from Gotto and Pownall 1999b.
2.3.3.1. The good lipids and reverse cholesterol transport
Removal of excess cholesterol from the arterial wall and other peripheral
tissues and its transportation to the liver for degradation is called reverse
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cholesterol transport (RCT) (Tall 1998). RCT is a multi-step process offer-
ing protection against CAD. 
The first step in the RCT is cholesterol efflux from cell membranes to
acceptor particles such as high-density lipoprotein (HDL) (von Eckardstein
and Assmann 1998). HDL is an important factor in RCT, and several stud-
ies have shown an inverse relation between serum HDL levels and inci-
dence of CAD (Castelli et al. 1986, Gordon et al. 1989, Goldbourt et al.
1997). HDL includes a group of particles varied in function and structure
(von Eckardstein and Assmann 1998). Most of the lipid-rich HDL parti-
cles, α-LpA-I, contain apolipoprotein A-I (apoA-I) as their major protein
constituent. The minor HDL subclasses preβ1-LpA-I, γ-LpE, LpE, and LpA-
IV, however, are considered to be initial and fast acceptors of cell-derived
cholesterol and are important contributors to cholesterol efflux capacity,
particularly in conditions with apoA-I deficiency (von Eckardstein and Ass-
mann 1998).
In RCT, HDL acts in conjunction with lecithin:cholesterol acyltransferase
(LCAT), an enzyme that esterifies cholesterol (Tall 1998). Cholesteryl ester
in HDL can later be taken up in the liver via particle uptake, or in liver or
other tissues with the help of cell-membrane proteins. In addition, choles-
teryl ester can be transferred to triglyceride-rich lipoproteins (TRL) by cho-
lesteryl ester transfer protein (Tall 1998). In addition to LCAT-dependent
cholesterol efflux onto HDL, lipid-free apolipoproteins can act independ-
ently from LCAT (von Eckardstein and Assmann 1998).
For more than 20 years, the receptor-mediated control of plasma LDL
levels has been well understood; it has been the main focus for pharma-
cologic treatment of hypercholesterolemia. In addition, cell membrane
proteins play an important role in the RCT (Rothblat et al. 1999). The level
of expression of the scavenger receptor class B, type I (SR-B1), a member
of the class B scavenger receptors, correlates both with the selective
transfer of cholesteryl ester into cells and with cholesterol efflux from
cells (Fidge 1999). ATP-binding cassette transporter 1 (ABCA1), a gene
encoding the cholesterol efflux regulatory protein, has recently been iden-
tified as the major gene underlying the HDL deficiency in Tangier disease,
a condition associated with reduced cholesterol efflux and premature ath-
erosclerosis (Brooks-Wilson et al. 1999, Marcil et al. 1999). Furthermore,
common genetic variation within the ABCA1 region was recently found to
be associated with decreased HDL cholesterol level, increased triglyc-
erides, and an increased risk for CAD (Clee et al. 2000 and 2001). 
Different efflux mechanisms may operate under different circumtances,
depending on factors such as tissue location, metabolic state of the cell,
and type of extracellular acceptors (Rothblat et al. 1999). 
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HDL is commonly separated into 2 subfractions: the lighter and larger
HDL2 and denser and smaller HDL3 (Eisenberg 1984). The Physicians’
Health Study demonstrated the protective effects of both the HDL3 and
HDL2 subfractions against risk for MI (Stampfer et al. 1991). However, a
Finnish study suggested that HDL2 levels may play a more important pro-
tective role than do levels of the HDL3 subfraction (Salonen et al. 1991).
2.3.3.2. The bad lipids...and diabetic dyslipidemia in a nutshell
The most important contributor to the formation of atherosclerosis is LDL,
the main cholesterol carrier in human plasma (Kannel et al. 1979). LDL
comprises particles of varying density and size, and of these different
subclasses of LDL, small and dense LDL particles have the most athero-
genic potential (Austin et al. 1996). As reviewed by Gotto and Pownall
(1999c), an increasing body of evidence indicates the importance of TRL
particles, very low-density lipoprotein particles (VLDL), and chylomicrons
and their remnants. 
In type 2 diabetes there occur complicated alterations in lipoprotein
metabolism both in the fasting state and especially postprandially (Mero
et al. 1998 and 2000, Evans et al. 1999). A low plasma concentration of
HDL cholesterol and high triglyceride levels are the main lipoprotein
abnormalities in type 2 diabetes (Kannel 1985, Taskinen 1990). The
pathogenesis of this dyslipidemia is complex. Hypertrigyceridemia and
overproduction of triglyceride-rich VLDLs in type 2 diabetes are caused by
the impaired inhibitory effect of insulin on hepatic apoB100-containing
particle synthesis and accelerated free fatty acid (FFA) delivery to the liver
(Malmström et al. 1997 and 1998, Evans et al. 1999). In addition to over-
production of TRLs, VLDL, and chylomicrons, their catabolism is simulta-
neously reduced due to altered function of insulin-sensitive lipoprotein
lipase (De Man et al. 1996). Serum concentration of triglycerides has
been shown to be the critical factor in regulation of the properties of LDL
particles. HDL and LDL are enriched with triglycerides, and increased
lipolysis by hepatic lipase results in smaller and more dense lipoprotein
particles (Siegel et al. 1996, Taskinen et al. 1996). Small and dense LDL
particles that are atherogenic are thus directly related to hypertrigyc-
eridemia rather than to diabetes per se (Syvänne and Taskinen 1997). 
In addition to the atherogenic changes seen in LDL particles, composi-
tional changes in HDL particles in type 2 diabetes reduce their antiathero-
genic capacity (Gowri et al. 1999). In type 2 diabetic patients, there is an
impaired antiatherogenic potential of lipoprotein which contains apoA-I
but not apoA-II (LpA-I) particles (Cavallero et al. 1995). In men with type 2
diabetes, low concentrations of lipoprotein containing both apoA-I and
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apoA-II (LpA-I:A-II) particles, and low serum apolipoprotein A-I (apoA-I), and
serum apolipoprotein A-II (ApoA-II) concentrations, and low HDL3 choles-
terol are indicators for CAD (Syvänne et al. 1995). Furthermore, the
capacity of patient plasma to induce cholesterol efflux from Fu5AH cells,
reflecting the RCT, is impaired in type 2 diabetic patients compared with
healthy controls (Syvänne et al. 1996).
The atherogenic alterations in lipoprotein metabolism in type 1 diabetes
differ from those seen in type 2 diabetes. The development of CAD in type
1 diabetic patients is related to the degree of nephropathy (Jensen et al.
1987). Indeed, type 1 diabetic patients without complications have even
an antiatherogenic lipoprotein profile characterized by normal levels of
LDL cholesterol and elevated HDL cholesterol concentrations (Howard
1987). As nephropathy develops, the lipoprotein pattern turns athero-
genic (Vannini et al. 1984, Haaber et al. 1992). Hypercholesterolemia,
together with hypertension, is a major predictor of death in the type 1 dia-
betic population (Krolewski et al. 1994). Growing evidence exists that in
diabetic patients genetic factors are related to development of nephropa-
thy (Quinn et al. 1996). Interestingly, in patients with type 1 diabetes, a
family history of type 2 diabetes raises susceptibility to diabetic nephropa-
thy (Fagerudd et al. 1999).
2.3.4. Factors beyond lipids... 
2.3.4.1. Gender
Epidemiological studies, including the Framingham Study, have demon-
strated that men have higher morbidity and mortality rates as a result of
CAD than do women, particularly premenopausal women (Kannel and
Wilson 1995). However, this applies to the nondiabetic population, and
diabetes abolishes the gender difference. 
Despite a few negative reports (Butler et al. 1985, Kleinman et al. 1988),
several epidemiological studies have shown that any type of diabetes
increases the risk for CAD to a greater extent in women than in men (Bar-
rett-Connor and Wingard 1983, Pan et al. 1986, DeStefano et al. 1993,
Kannel and McGee 1979b). A meta-analysis by Kereiakes (1985) showed
that in a diabetic population men and women have a similar risk for MI,
but diabetic women suffered 40% greater mortality from MI than did dia-
betic men. Furthermore, in a prospective cohort study with 1 935 patients
hospitalized with a confirmed acute MI, the risk of death during the
follow-up of 3.7 years was higher in diabetic women without previous CAD
than in those nondiabetic women who had suffered an acute MI previ-
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ously (Mukamal et al. 2001). The relative risk for CAD and related mortal-
ity is only partly explained by an excess of the classic risk factors
observed in the diabetic population (Howard et al. 1998). 
In addition to epidemiological data, Colhoun and coworkers (2000) have
recently shown, in type 1 diabetic patients, a loss of gender difference in
coronary artery calcification. In their study, calcification of the coronary
vessels was measured with electron-beam computed tomography (EBCT)
in a prospective population-based setting.
2.3.4.2. Hyperglycemia
Studies on nondiabetic subjects have observed that even slightly elevated
serum glucose concentrations increase risk for cardiovascular disease
(Laakso 2000). In both type 1 and type 2 diabetic patients, epidemiologi-
cal data have revealed hyperglycemia to be a major player in the develop-
ment of the microvascular (diabetic retinopathy, loss of vision, and
nephropathy) and macrovascular (CAD, stroke, and peripheral vascular
disease) complications (Klein 1995, Laakso 1999). 
Data from prospective clinical studies in type 2 diabetic patients have
shown an association between level of hyperglycemia and increased risk
for microvascular disease (Pirart 1978, Klein 1995, the United Kingdom
Prospective Diabetes Study (UKPDS) Group 1998), for MI (Kuusisto et al.
1994), and for mortality due to macrovascular disease (Uusitupa et al.
1993, Standl et al. 1996, Lehto et al. 1997). Intensive blood-glucose con-
trol with sulphonylureas or insulin compared with conventional treatment
seemed mainly to improve microvascular outcomes, with only borderline
reduction in MI (P = 0.052) in UKPDS 33 study (the UKPDS Group 1998).
The recently published observational UKPDS 35 study confirmed earlier
findings showing that any reduction in mean glycosylated hemoglobin A1c
(HbA1c) is likely to reduce diabetic complications. Indeed, every 1% reduc-
tion in HbA1c was associated with significant risk reduction: 21% for
death, 14% for MI, and 37% for microvascular complications of type 2
diabetes (Stratton et al. 2000). Among patients with type 1 diabetes, the
Diabetes Control and Complications Trial showed that intensive therapy
for hyperglycemia markedly reduces the risk for microvascular complica-
tions as compared to conventional therapy. In that study, the risk for
macrovascular and peripheral disesase was reduced by 41%; however,
this result was nonsignificant (The Diabetes Control and Complications
Trial Research Group 1993). In type 1 diabetes patients without
nephropathy, poor metabolic control is a strong independent predictor of
coronary events (Lehto et al. 1999).
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The exact cellular links between elevated blood glucose levels and CAD
remain incompletely understood. The adverse effects caused by long-last-
ing hyperglycemia are likely to be mediated by several pathways. One of
the most interesting of these is the formation of sugar-derived advanced
glycosylation end-products (AGEs) within the arterial wall (Brownlee et al.
1988). Collagen-linked AGEs induce pathological effects on vascular wall
homeostasis by cross-linking plasma proteins, inducing cytokine and
growth-factor release, and increasing oxidative stress (Nakamura et al.
1993, Kiuchi et al. 2001). 
2.3.4.3. Metabolic syndrome 
Metabolic syndrome, also called as ”Syndrome X” or ”the Insulin Resis-
tance Syndrome”, is characterized by a cluster of risk factors associated
with increased risk for CAD. WHO has recently published a working defini-
tion for the metabolic syndrome to overcome the long-standing lack of
any internationally agreed-upon definition (WHO 1999). 
According to WHO, ”glucose intolerance, IGT or diabetes mellitus and/or
insulin resistance together with 2 or more of the other following compo-
nents are needed for the recognition of metabolic syndrome: a) impaired
glucose regulation or diabetes, b) insulin resistance (under hyperinsuline-
mic, euglycemic conditions, glucose uptake below lowest quartile for back-
ground population under investigation), c) raised arterial pressure
≥ 140/90 mmHg, d) raised plasma triglycerides (≥ 1.7 mmol/l) and/or low
HDL-cholesterol (< 0.9 mmol/l in men; < 1.0 mmol/l in women), e) central
obesity (males: waist to hip ratio > 0.90; females: waist to hip ratio > 0.85)
and/or body mass index (BMI) > 30 kg/m2 and f) microalbuminuria (urinary
albumin excretion rate ≥ 20 µg/ min or albumin:creatinine ratio ≥ 30 mg/g)”
(WHO 1999).
Insulin resistance seems to be the fundamental abnormality both in meta-
bolic syndrome and in type 2 diabetes (Reaven 1988, Ferrannini et al.
1991, Haffner et al. 1992, Haffner 1999, WHO 1999). The progression
from normal glucose tolerance and/or IGT to type 2 diabetes occurs when
the insulin secretory function fails to produce more insulin to overcome
muscle and adipose tissue insulin resistance (Reaven 1988). Furthermore,
insulin resistance, by affecting the metabolism of FFAs, seems to be the
key contributor to the dyslipidemia related to type 2 diabetes (Syvänne and
Taskinen 1997), as discussed earlier in section 2.3.3.2. Postprandial
lipemia may be a mechanistic link between insulin resistance and CAD
(Haffner 1999, Mero et al. 2000). The exact pathogenetic mechanisms
behind the metabolic syndrome, plus the complicated interactions
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between its different components remain unclear (Haffner 1999). The
hunt for the ”still missing factors” between the components of the meta-
bolic syndrome is ongoing. A unique signaling molecule, resistin, secreted
by adipocytes was recently found in animal models (Steppan et al. 2001).
However, its role in human metabolism still remains unclear (Nagaev and
Smith 2001).
Besides the factors listed above, several others are often associated with
the metabolic syndrome (WHO 1999). In addition, proatherogenetic prop-
erties of hyperinsulinemia and glucose intolerance may be mediated in
part by their potential to promote factors related to acute thrombosis,
according to Meigs et al. (2000). Elevated levels of fasting insulin are
associated with impaired fibrinolysis and hypercoagulability even in sub-
jects with normal glucose tolerance. Patients with diabetes mellitus have
increased fibrinogen levels and plasminogen activator inhibitor 1, and,
not surprisingly, 80% of patients with diabetes mellitus die due to causes
related to acute thrombosis (Carr 2001). 
The association of hyperinsulinemia with CAD has been a subject of inter-
est in several studies. The Helsinki Policemen Study (Pyörälä K 1979,
Pyörälä M et al. 1998), among other prospective studies, has shown that
high plasma insulin is an independent, though weak, predictor of CAD.
Furthermore, in men undergoing elective coronary angiography who had a
normal oral glucose tolerance test, fasting and 2-hour plasma insulin con-
centrations were independent predictors of the presence and severity of
CAD (Spallarossa et al. 1994). In elderly type 2 diabetic men, components
of the Insulin Resistance Syndrome (high fasting insulin, high BMI, high
waist-to-hip ratio, high total triglycerides, and short duration of diabetes)
predicted coronary events in a recent study by Kuusisto et al. (2001).
2.3.4.4. Microalbuminuria and nephropathy
A component of metabolic syndrome, microalbuminuria, is an independ-
ent risk factor for cardiovascular morbidity and even for death among
nondiabetic and diabetic subjects (Yudkin et al. 1988, Gerstein et al.
2001). A highly increased risk for CAD is connected with occurrence of
hyperinsulinemia and microalbuminuria together (Kuusisto et al. 1995). In
patients undergoing clinically indicated angiography, urinary albumin
excretion and their fasting serum insulin levels are directly related to the
severity of CAD (Tuttle et al. 1999). 
The presence of nephropathy increases the risk for CAD in type 1 diabetic
patients by a factor of 10. The reason for this phenomenon remains
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unknown, but may be related to differences in risk factors such as hyper-
tension, and in lipids and lipoproteins affected by genetics (Tuomilehto et
al. 1998). 
2.3.4.5. Family history
The genetic basis of CAD is likely to lie in many genes that in some way
are abnormal. The Framingham study (Myers et al. 1990) and several
other studies have shown that family history is an independent risk factor
for CAD (Williams 1984, Hopkins et al. 1988, Sharp et al. 1992,
Roncaglioni et al. 1992). More than half the patients with premature CAD
have a lipoprotein disorder (Davignon and Genest 1998). It is probable
that genetic factors determine the limits under which CAD develops
(Pajukanta et al. 1998), but environmental factors such as diet, smoking,
and exercise influence the risk already genetically determined (Hegele
1997, Superko 1998). Of those that have had a CAD diagnosis before the
age of 55, over 50% are members of high-risk families (Williams 1984). 
In Finland, a family history of CAD is a stronger risk factor for mortality
than is a family history of type 2 diabetes (Kekäläinen et al. 1996). Inter-
estingly, the former is a risk factor for CAD in type 1 diabetic patients,
and insulin resistance may also be an important factor in some patients
with type 1 diabetes (Erbey et al. 1998). Thus, strong evidence exists for a
genetic component behind both CAD and diabetes (Williams 1984, Hop-
kins et al. 1988, Myers et al. 1990, Roncaglioni et al. 1992, Kekäläinen
et al. 1996, Watanabe et al. 1999).
2.3.4.6. Smoking
Epidemiological data have shown that in the general population cigarette
smoking is a powerful risk factor for CAD (LaCroix et al. 1991, Tverdal et
al. 1993). This modifiable habit is extremely harmful for diabetic patients,
as shown in the UKPDS trial (Turner et al. 1998), and for subjects with a
family history of CAD (Hopkins et al. 1984). It has been suggested that up
to 70% of the excess deaths in high-risk families may be explained by the
interaction between smoking and family history of CAD (Khaw and Barrett-
Connor 1998). Furthermore, in one study, 46% of premature MIs were
related to the interaction between a genetically determined prothrombotic
factor and smoking (Ardissino et al. 1999). In Asian countries, in popula-
tions with low cholesterol levels, smoking is a major independent risk
factor for CAD; their low cholesterol level provides no protection against
this smoking-related disease (Jee et al. 1999). 
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2.3.4.7. Homocysteine
Homocysteine is an amino acid formed during the normal metabolism of
the amino acid methionine (Eikelboom et al. 1999). The notion of the
atherogenicity of homocysteine came into existence when the relation
between premature atherosclerosis and homocysteinuria was observed
in subjects with a genetic disorder causing severe hyperhomocysteinemia
(McCully 1969). 
Many cross-sectional and retrospective observational studies suggest that
an elevated level of homocysteine in blood is a common and independent
risk factor for CAD, as recently extensively reviewed by Glenn and Duell
(1999), Eikelboom et al. (1999), Nygård et al. (1999), and Thambyrajah
and Townend (2000). However, data from prospective studies remain less
conclusive (Eikelboom et al. 1999). Two prospective Finnish studies have
found no significant correlation between homocysteine and risk for coro-
nary events (Alfthan et al. 1994, Voutilainen et al. 2000). One recent
cross-sectional study found an association with MI but not with uncompli-
cated CAD (Nikkari et al. 2001). 
Chao et al. (1999) reported that hyperhomocysteinemia has a graded
effect on risk for CAD as well for as the severity and extent of coronary
atherosclerosis. In patients with angiographically defined CAD, increased
blood homocysteine levels seem to be a significant predictor of mortality
(Anderson et al. 2000). 
Mechanisms causing the adverse effects of homocysteine remain
unknown, but several hypotheses have been suggested: endothelial
injury, platelet activation, and oxidation of LDL (Thambyrajah and Tow-
nend 2000).
2.4. CORONARY ANGIOGRAPHY IN QUANTIFICATION OF CAD
2.4.1. History and the current position of coronary angiography
Visualization of coronary atheromatosis is needed for clinical and
research purposes. This information contributes to therapeutic decisions
as well as to our understanding of the pathophysiology of CAD. The first
radiographic visualizations of the coronary tree were performed with a
direct aortic root needle puncture or surgical placement of catheters. The
technical limitations yielded poor images, and the patients were exposed
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to toxic contrast media and high radiation doses (Amplatz 1991). In 1937,
Castellanos was the first to introduce a method in which contrast medium
was administered via a peripheral vein (Castellanos et al. 1937), and
Sones performed the first selective coronary angiography more than 40
years ago (Mueller and Sanborn 1995). Today, cardiovascular catheteriza-
tion and related therapeutic interventions are safe and effective clinical
tools (Bittl 1996). 
Recently, there has been a rapid development in angiographic image pro-
cessing (Sheenan et al. 1997). A few years ago, the 35 mm cine film was
the only practical medium for the storage of coronary angiograms (Reiber
et al. 1995). However, at the moment, digital storage is widely replacing
the older systems, and almost without exception, new cardiac catheteri-
zation laboratories are entirely digital (Sheenan et al. 1997). 
2.4.2. Limitations of coronary angiography and visual analysis 
The limitations of coronary angiography are well recognized, starting from
the very obvious – viewing 3-dimensional vascular structure in only 2
dimensions (Katritsis and Webb-Peploe 1991). Moreover, visual interpre-
tation of angiograms is hampered by intra- and interobserver variability in
analysis (Detre et al. 1975, DeRouen et al. 1977, White et al. 1984). 
Factors related to vascular remodeling also hinder use of this technique.
In a response to preserve lumen dimensions, atherosclerotic vessels have
a tendency to dilate (Glagov et al. 1987). The external diameter of the
vessel increases in order to normalize the lumen, as shown in Figure 1.
Measuring only lumen dimensions thus sometimes offers only a poor esti-
mate of plaque volume in diffuse CAD (Glagov et al. 1987, Escaned et al.
1996). Furthermore, use of any remodeled vessel’s diameter as a refer-
ence diameter for another stenotic segment may lead to biased results
(Glagov et al. 1987, Davies 1998). 
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Figure 1. Coronary remodeling. Constant lumen size is maintained until the
plaque occupies about 40% of the area defined by the internal elastic lamina
(Glagov et al. 1987). 
Interpretation of available data concerning the severity of CAD is ham-
pered by variation among methods of classification of CAD characteristics
applied in different studies (Selzer 1982, Gensini 1983). In the literature,
the definition of CAD severity was earlier often based on descriptive terms
such as: ”marked,” ”significant,” ”mild,” ”moderate,” ”severe” (Waller et
al. 1980). A widely used method, the classification of CAD into a 1-, 2-, or
3-vessel disease, is also considered inadequate (Selzer 1982). To make
reporting more consistent, several semi-quantitative scoring systems have
been introduced based on visual analysis of coronary angiograms, both
quantitative and qualitative (Hamby et al. 1976, Brandt et al. 1977, Dor-
timer et al. 1978, Hasin et al. 1979, Gensini 1983, Hamsten et al. 1986,
Moise et al. 1988, Sullivan et al. 1990, Wilson et al. 1999b). 
2.4.3. Quantitative coronary angiography
Computer-assisted quantitative analysis of coronary angiograms, com-
monly shortened to ”quantitative coronary angiography” (QCA), was devel-
oped to improve clinical and research reliability (De Feyter et al. 1991).
The QCA was introduced for the first time in the late 1970s and has rap-
idly displaced visual analysis in interventional studies and also in the esti-
mation of the progression or regression of CAD (Reiber et al. 1993). 
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The functional impact of any 50% stenosis depends on the diameter of
the vessel. Visual analysis can provide us with only relative measures of
stenosis, but, if needed, QCA analysis can produce actual measure-
ments (De Feyter et al. 1991). Furthermore, relative measures such as
diameter stenosis are in visual analysis determined by comparing the
diameter of the maximal vessel reduction with the diameter of the site
that seems to be ”normal” (De Feyter et al. 1991). These ”normal” sites
in vessels, however, may either be dilated or diffusively narrowed. This
affects the calculation of percent diameter stenosis. By QCA analysis one
can get an estimate of predisease reference contours and luminal con-
tours, and thus an interpolated reference diameter value (De Feyter et al.
1991).
There are several commercial packages for QCA analysis for both
common image storing modalities: 35 mm cinefilm and digital (Reiber et
al. 1995). To utilize angiographic data on 35 mm cinefilms, the selected
cineframes are magnified and digitized by a converter and saved into
computer memory (Reiber et al. 1993). The digitized images are analyzed
with a QCA software package. The simplified steps of this analysis are:
calibration of the image data and segment definition and automated
detection of the arterial contours and their analysis (Reiber et al. 1993).
Calibration is needed prior to analysis to determine absolute vessel and
obstruction sizes. This procedure that yields a calibration factor is based
on the known French catheter size or on measurement of the contrast
catheter and use of automated edge detection of this catheter. The first
step in the coronary analysis is the definition of the start- and end-point of
the segment under analysis. Automated detection of the arterial contours
is carried out by the software. Manual corrections may be utilized, but
generally the user interaction is limited to defining the start- and end-
points of the vessel (Reiber et al. 1993). To avoid any bias caused by vas-
cular remodeling, as discussed earlier in this section, the QCA analysis
determines the interpolated reference diameter value that is an estima-
tion of vessel size prior to stenosis (Reiber et al. 1993). 
QCA analysis produces several clinically relevant parameters (see Figure
3, section 5.4.), of which only a few are listed here: minimum segment
diameter (mm), percentage diameter stenosis (PDS) (%), segment length
(mm), plaque area (mm2), segment area (mm2). Validation studies have
shown that QCA analysis produces data that are repeatable and objective
and show minimal inter- or intraobserver variability (Reiber et al. 1993,
Syvänne et al. 1994).
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2.4.4. New techniques: IVUS, EBCT, magnetic resonance
angiography
Intravascular ultrasound (IVUS) is the best new diagnostic tool since coro-
nary angiography, which appeared in the 1930’s (Nissen et al. 1993).
However, this is chiefly for research and special situations. For routine
use it is expensive and too invasive. Noninvasive EBCT coronary calcium
scanning offers a valid non-invasive method to judge the atherosclerotic
plaque burden (Sangiorgi et al. 1998). Despite this benefit, recent guide-
lines recommend against using coronary artery calcification detection rou-
tinely; it may not offer more information than do other methods (Taylor et
al. 2001).
Magnetic resonance angiography is a particularly attractive technique
without any invasive action or ionizing radiation. A recent study on mag-
netic resonance coronary angiography showed adequate visualization in
85% to 91% of the proximal coronary arterial branches and in 38% to
76% of the middle and distal branches (van Geuns et al. 2000). In order
to replace the established methods, magnetic resonance coronary
angiography must become relatively inexpensive, with good sensitivity
and specificity (Hunink et al. 1999). Thus, coronary angiography remains
now and in the forseeable future the main tool for imaging coronary
arteries.
2.5. SEVERITY AND EXTENT OF CAD IN DIABETIC PATIENTS
2.5.1. Severity and extent of CAD in diabetic patients – previous
studies 
The basis for increased cardiovascular morbidity and mortality in diabetic
patients is not completely understood. The common clinical opinion sug-
gests that diabetic patients with CAD have an extensive and diffuse type
of disease affecting particularly the distal parts of the coronary vessels
(Nesto 1998, Timmis 2001). However, this view is only partly supported by
previous studies (Table 2), and it is unclear to what extent other diabetes-
related mechanisms such as autonomic nervous system dysfunction,
impaired fibrinolysis, endothelial cell dysfunction, and impaired microvas-
cular function explain the adverse outcome of diabetic CAD patients
(Aronson et al. 1997, Timmis 2001).
Of the 15 studies exploring the severity and extent of diabetic CAD in
Table 2, 11 have revealed that diabetic patients have more severe and/or
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extensive CAD than do nondiabetic subjects (Hamby et al.1976, Crall et
al. 1978, Dortimer et al. 1978, Vigorita et al. 1980, Vigorito et al. 1980,
Wilson et al. 1983, Valsania et al. 1991, Calton et al. 1995, Melidonis et
al. 1999, Cariou et al. 2000, Natali et al. 2000). However, in 3 of these
studies, CAD diffuseness between diabetic and nondiabetic subjects was
equal (Dortimer et al. 1978, Calton et al. 1995, Cariou et al. 2000). Fur-
thermore, there are at least 4 studies that have reported no difference in
the severity and extent of CAD or its diffuseness between diabetic and
nondiabetic patients (Verska and Walker 1975, Waller et al. 1980, Abadie
et al. 1983, Hochman et al. 1988). Waller et al. (1980) found, however,
more left main CAD in the diabetic group.
The conflicting data (Table 2) in the earlier studies may in part be
explained by the following issues: (1) In 8 of 15 of the studies, the type 1
and type 2 diabetic patients have not been separated. (2) Variation has
occurred in the inclusion criteria of the studies, for example with regard to
reason for angiography. (3) Different definitions of extent and severity of
CAD have been used as well as different scoring systems based on visual
analysis of angiograms. (4) Matching of the study groups was performed
in only some of the studies.
In addition to smaller size studies, much of the existing data on severity
and extent of CAD in diabetic patients come from subgroup analyses of
the large thrombolytic or interventional studies. Subgroup analysis of
the TAMI trial and GUSTO-I study concluded that diabetic participants
have more severe CAD than do nondiabetic subjects (Granger et al.
1993, Woodfield et al. 1996). However, in these studies the diabetic
subjects were more often female or hypertensive or older than nondia-
betic participants. Often these data are lacking details on diabetes
management. 
2.5.1.1. Studies including only patients with type 1 diabetes
Only 2 studies exploring the severity and extent of CAD have included
specifically type 1 diabetic patients; both of these studies reported more
advanced CAD in the diabetic group. Crall and Roberts (1978) reported
autopsy findings of 9 young type 1 diabetic patients and matched nondia-
betic ones. The diabetic patients had more extramural coronary luminal
narrowing by atherosclerotic plaques than did the control subjects. In
addition, the percentage of total arterial length that was narrowed > 50%
of the cross-sectional area was 47% in the diabetic group and 1% in the
nondiabetic group controls. 
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Valsania and colleagues (1991) used visual evaluation of coronary
angiograms when they analyzed 32 type 1 diabetic patients and 31 non-
diabetic subjects undergoing elective coronary angiography for symptoms
of CAD. In line with the study by Crall and Roberts (1978), diffuse narrow-
ings and multivessel disease were more prevalent in their diabetic than in
their nondiabetic group (Valsania et al. 1991).
2.5.1.2. Studies including only patients with type 2 diabetes
Five studies have specifically studied severity and extent of CAD in type 2
diabetic patients. A postmortem study by Waller et al. (1980) found, in
diabetic and nondiabetic subjects, a similar proportion of significally dis-
eased coronary arteries in the 3 major coronary branches. However, they
reported a greater incidence of left main coronary artery stenosis among
diabetics. Vigorita et al. (1980) found more diffuse CAD and a higher
number of CAD-involved vessels in the ”adult onset” diabetic group than
in nondiabetic controls. Calton et al. (1995) have observed that the coro-
nary score was significantly higher in 75 type 2 diabetic patients than in
matched nondiabetic subjects. In contrast to Vigorita et al. (1980), they
observed equally diffuse CAD between diabetic and nondiabetic patients.
Hamby et al. (1976) found higher coronary scores and more 3-vessel CAD
in combined type 2 diabetic and IGT groups than in their nondiabetic
group, each group comprising 100 subjects. However, in this well-con-
ducted angiographic study, the difference was confined to patients with
hypertriglyceridemia (Hamby et al. 1976). Recently, Natali and coworkers
(2000) reported data on 2 253 type 2 diabetic patients undergoing coro-
nary angiography. That study, however, also included patients investigated
for reasons other than suspected CAD. Diabetic patients had more 3-
vessel disease and had higher atherosclerosis scores than did nondia-
betic controls. After adjusting for risk factors, the difference in atheroscle-
rosis scores between diabetic and non-diabetic subjects was greater in
women than in men. 
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3. AIMS OF THE STUDY
Studies have shown contradictory results with regard to severity and
extent of CAD in the diabetic population. Thus far, to the best of our
knowledge, no data based on a QCA-derived scoring method for CAD have
appeared. Therefore, the aims of the present study were:
1. To create a scoring system for evaluation of the severity and extent of
CAD, based on computer-aided QCA.
2. To discover whether the angiographic severity and extent of CAD differ
quantitatively between type 2 diabetic and nondiabetic, and type 1
diabetic and nondiabetic patients undergoing clinically indicated coro-
nary angiography.
3. To investigate risk factors that may be related to the anatomical distri-
bution and severity and extent of CAD.
4. To study whether the capacity of plasma to induce cholesterol efflux
from cultured Fu5AH rat hepatoma cells predicts the severity and
extent of CAD. 
5. To investigate the determinants of the severity and extent of CAD in
subjects from high-risk families with no diagnosis or symptoms of CAD
at the time of angiography.
4. SUBJECTS AND STUDY DESIGNS
Table 3. Characteristics of study subjects.
Number Male/ Age (yrs) BMI Angiography 
Female (kg/m2) indication
Studies I-II
Type 2 DM 55 48/7 56 (51, 59) 29 (27, 31) Clinical, symptoms of CAD
Nondiabetic 55 48/7 55 (51, 59) 29 (27, 30)
Study III
Type 2 DM 46 46/- 56 (50, 59) 30 (27, 31) Clinical, symptoms of CAD
Nondiabetic 42 42/- 55 (51, 59) 30 (28, 31)
Study IV
Type 1 DM 64 40/24 47 (42, 53) 24 (23, 27) Clinical, symptoms of CAD
Nondiabetic 64 40/24 48 (41, 52) 27 (23, 30)
Study V
DM + IGT 22 14/8 52 (49, 59) 30 (27, 34) Study purposes, 
Nondiabetic 29 14/15 56 (49, 63) 27 (25, 29) asymptomatic for CAD
Data are median with (25th, 75th percentile).
Studies I and II. The study population consisted of 57 (50 male and 7
female) consecutive type 2 diabetic patients undergoing clinically indi-
cated elective coronary angiography at Helsinki University Central Hospi-
tal between September 1989 and February 1992. Each patient had type
2 diabetes fulfilling the WHO 1980 criteria and, in coronary angiogram, at
least one > 50% severe stenosis. A corresponding number of nondiabetic
CAD patients were individually matched with type 2 diabetes patients by
sex, age (within 5 years), and BMI (within 2 kg/m2). The control subjects
had normal fasting glucose and HbA1c values. The groups included an
equal number of smokers. Two matched pairs were excluded from the
QCA analysis; thus, the study comprised 55 matched pairs, 48 male and
7 female.
Study III. Based on the same study population as in Studies I and II, this
study comprised 46 men in the diabetic and 42 men in the nondiabetic
group, for whom data were available both on the in vitro potential of
patient plasmas to induce cholesterol efflux from Fu5AH cells and on the
results of QCA analysis. 
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Study IV. Patients with type 1 diabetes who underwent cardiac catheteri-
zation for symptoms of CAD at the Helsinki University Central Hospital
between 1982 and 1997 were identified. All the 72 patients had previ-
ously diagnosed diabetes fulfilling the WHO 1980 criteria for type 1 dia-
betes mellitus. Nondiabetic controls from the same population were
matched individually with the diabetic patients for sex, age (within 
5 years), date of angiography (within 3 years), and serum creatinine
value (< 100, 100 – 300, > 300 µmol/l or dialysis). Clinical data were
retrieved from catheterization reports and medical records. The final
study groups consisted of 64 pairs, because 8 pairs had to be excluded
for technical reasons. 
Study V. This study comprised asymptomatic members of high-risk fami-
lies who were siblings of patients with premature severe CAD. The high-
risk families were identified at Kuopio University Hospital. Inclusion crite-
ria for the probands were: 1) age at time of CAD diagnosis < 55 years in
men and < 65 years in women, 2) stenoses > 50% at least in 2 coronary
arteries, and 3) family history of premature CAD. Families were included if
at least one other sibling in addition to the proband fulfilled the inclusion
criteria or had a history of definite MI. The final study group comprised 51
subjects, 23 women and 28 men, because one of the subjects was
excluded for technical reasons. Subjects were classified into 3 groups:
diabetic (DM), IGT or normal glucose tolerance. The combined DM and
IGT group comprised 22, and the nondiabetic group 29 subjects.
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5. METHODS
5.1. CORONARY ANGIOGRAPHY 
Coronary angiography, in all studies, was performed by the percutaneous
femoral approach by standard angiographic techniques, and was
recorded on 35-mm cine film. To control vasomotor tone, sublingual nitro-
glycerine was administered routinely.
5.2. FRAME SELECTION 
All stages of the analysis were performed fully blinded to the identity and
diabetic status of the patients. A cardiologist evaluated the angiograms
visually and selected optimal single-view frames for QCA analysis of the
entire coronary tree. Based on this visual preliminary analysis, a sketch
was drawn indicating the segments and stenoses to be analyzed with
QCA. 
5.3. SEGMENTAL CLASSIFICATION OF THE CORONARY TREE 
Classification of the coronary tree is illustrated in Figure 2. Coronary seg-
ments were analyzed in one angiographic view and classified into 4 cate-
gories. The left main coronary artery was considered a segment of its
own. Proximal segments comprised the proximal parts of the left anterior
descending, the left circumflex, and the right coronary artery. Mid-seg-
ments consisted of the mid-parts of the 3 main coronary arteries, and of
the proximal 1 to 2 cm of major diagonal and obtuse marginal branches.
Segments distal to mid-segments were considered distal segments.
Whenever anatomically and technically possible, distal segments also
included the posterolateral branches of the left circumflex and right coro-
nary arteries, the right ventricular branch, the acute marginal branch, and
the second diagonal and obtuse marginal branches.
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Figure 2. Segmental classification of the coronary tree, indicating proximal
(light gray), mid- (dark gray), and distal (white) coronary segments. LM, left
main coronary artery; LAD, left anterior descending coronary artery; LD, left
diagonal branch; LCX, left circumflex coronary artery; LOM, left obtuse mar-
ginal branch; LPL, left posterolateral branch; RCA, right coronary artery; RPD,
right posterior descending branch; RPL, right posterolateral branch.
5.4. QUANTITATIVE CORONARY ANGIOGRAPHY 
Third-generation QCA software, the Cardiovascular Measurement System
(QCA-CMS®) version 3.0 (Medis, Nuenen, The Netherlands) was used in
QCA analysis. Segments with a diameter of < 1.5 mm were excluded. A
stenosis was defined as a narrowing  > 25% diameter stenosis detected
by QCA analysis, or any narrowing recorded in the visual analysis. The
selected frame was optically magnified 2.3-fold and digitized into com-
puter memory. The boundaries of optically magnified and video-digitized
coronary segments and the contrast  catheter were defined by automated
edge-detection techniques. Catheter diameters were estimated as follows:
6 Fr = 1.95 mm, 7 Fr = 2.20 mm, and 8 Fr = 2.45 mm. 
An example of a quantitative analysis result page is presented in Figure 3.
After the user has defined the starting and ending points of the segment,
an arterial path through the segment in question is computed automati-
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LM
LCX
LOM
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RPL
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LAD
LPL
cally. In most cases, the interpolated reference diameter (Reiber et al.
1985) was used in calculating the PDS; however, the user-defined refer-
ence diameter was used occasionally to avoid underestimation of the dif-
fuse type of CAD (Reiber et al. 1995). A gradient field transform was used
for the quantification of complex coronary lesions (van der Zwet and
Reiber 1994, Reiber et al. 1995). Several obstuction- and vessel-related
parameters, such as maximal PDS, obstuction diameter, plaque area,
obstruction, and segment length, are provided in 2 printed results pages
like the ones shown as Figure 3. (Reiber et al. 1995).
In Study I, a repeat analysis of 6 randomly selected angiograms was per-
formed to test the intraobserver variability of the QCA analysis. 
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Figure 3. Figure shows a final results page of QCA-CMS® analysis of the proxi-
mal part of a left circumflex artery (LCX). In the upper panel are the automati-
cally detected luminal contours, the computer-defined reference contours, and
the diameter function. In the lower panel, the results page of the QCA analysis
is displayed with all detailed quantitative data. The percent diameter stenosis
here was 55.3%. 
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5.5. MEASURES OF SEVERITY, EXTENT, AND ATHEROMA
BURDEN 
By utilizing computer-aided QCA parameters, global severity, extent, and
overall atheroma burden indices (Figure 4) were counted to describe per
patient characteristics of CAD. These indices were separately calculated
for different coronary segments, i.e., the left main, proximal, mid-, and
distal segments, and also for different vessel territories: the left main, left
anterior descending, left circumflex, and right coronary artery.
Severity: Severity was defined as the tightest stenosis within a certain
coronary territory and was based on the PDS values. The global severity
index was counted as the average of the tightest stenosis measured in
the left main coronary, the left anterior descending, the left circumflex,
and the right coronary artery territories. The severity index was likewise
calculated for proximal, mid-, and distal segments of the coronary tree.
Extent: Extent indices were calculated as the sum of the stenosis lengths
within the segment divided by segment length. Furthermore, the extent
indices were calculated as the sum of the stenosis lengths divided by the
total lengths of the segments in different segment areas (left main, proxi-
mal, mid-, distal). The global extent index takes into account all the steno-
sis lengths and lengths of the segments measured in each subject in
question, and is calculated as the sum of all the stenosis lengths meas-
ured divided by the total length of all the segments available for analysis. 
Atheroma burden: Atheroma burden was derived from the plaque area
which represents a 2-dimensional projection of the area covered by ather-
osclerotic tissue within the stenosis. The sum of the QCA-determined
plaque areas within a certain segment was divided by the respective seg-
ment lengths, and the global atheroma burden index was the sum of all
the plaque areas measured divided by the total length of all the segments
available for analysis.
Thus, the global severity, extent, and overall atheroma burden indices
describe per-patient characteristics of CAD. 
Total occlusions: To avoid excluding data on the most severely diseased
vessels, an imputed per-group estimate value was calculated to represent
the segments with total occlusion or those distal to total occlusion. For
any occluded segment, the maximum stenosis length or plaque area
measured in the corresponding segment of any patient in that group was
taken to represent the pertinent value for that segment. The denominator
needed to calculate the extent and atheroma burden indices was the
length of the most severely diseased corresponding segment; however,
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this was adjusted for the average lengths of those segments within the
study group.
Figure 4. Schematic diagram of a coronary segment illustrating definitions of
the angiographic indices. The vessel (reference) diameter is 2.5 mm. The lesion
on the left has a minimum luminal diameter (MLD) of 0.50 mm, and therefore a
percent diameter stenosis (PDS) (measure of severity) of 80%. The length of
this lesion is 2.0 mm. The lesion on the right is less severe but longer. Segment
length is 10 mm; thus extent in this segment is 100 x (2 + 4 mm) /10 mm = 60%.
”Plaque areas” defining ”atheroma burden” are shown in black. 
5.6. LEFT VENTRICULAR FUNCTION ANALYSES 
Studies I, IV. Slager model left ventricular analysis (Slager et al. 1986)
version 3.0 (QCA-CMS®, Medis, Nuenen, The Netherlands), was used. In
addition to global ejection fraction values, this computer-based analysis
also estimates regional ejection fractions of anterobasal, anterolateral,
apical, inferoposterior, and posterobasal anatomical areas.
5.7. LABORATORY ANALYSES AND CLINICAL DATA 
Studies I, II, III. Venous blood samples were obtained after an overnight
fast. Lipoproteins (VLDL, intermediate density lipoprotein -IDL-, LDL, HDL,
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80% (PDS)
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SEVERITY = 80 %  (= tightest stenosis )
EXTENT = (2 mm + 4 mm) / 10 mm = 60%
ATHEROMA BURDEN = Σ plaque areas / segment length
HDL2 and HDL3) were determined as described earlier (Syvänne et al.
1995). Post-heparin plasma lipoprotein lipase and hepatic lipase activi-
ties were determined by a modification of the method of Huttunen et al.
1975, as is described in detail in Taskinen et al. (1988). Serum apoA-I
and apoA-II concentrations were measured by an immunoturbidimetric
method and apoB by immunochemical assay as described (Syvänne et al.
1995). The concentration of LpA-I particles was quantfied as decribed
(Parra et al. 1990). The LpA-I:A-II concentration was calculated by sub-
tracting the concentration of LpA-I particles from serum total apoA-I con-
centration. The capacity of patient plasma to induce cholesterol efflux
from cultured Fu5AH rat hepatoma cells was measured at INSERM, Insti-
tut Pasteur de Lille, France, according to the method of de la Llera Moya
et al. (1994). 
Study IV. Clinical data, including lipid and other laboratory parameters,
were retrospectively retrieved from catheterization reports and medical
records.
Study V. All laboratory analyses except homocysteine measurements
were carried out in Kuopio University Hospital. Plasma glucose was meas-
ured by the glucose oxidase method. Plasma insulin concentration was
determined by a commercial double-antibody solid-phase radioim-
munoassay. Serum FFAs were determined by an enzymatic method.
Lipoprotein fractionation was performed with ultracentrifugation and
selective precipitation. Serum apoA-I and apoB concentrations were
determined by an immunoturbidometric method. Urinary albumin was
determined by a simple dipstick test (positive if urinary albumin excretion
exceeded 0.3 g/l). Serum total homocysteine concentrations (tHcy) were
measured in the laboratory of the Department of Obstetrics and Gynecol-
ogy, Helsinki University Central Hospital, by a high-pressure liquid chro-
matographic method and fluorescence detection. 
5.8. STATISTICAL ANALYSES
All statistical analyses were performed with SYSTAT® for Windows soft-
ware, versions 6.0.1 and 7.0.1.
Study I. Comparisons between the study groups were performed by use
of the paired t test or Wilcoxon test for variables with continuous distribu-
tion. Categorical variables were analyzed with the Mantel-Haenszel test.
Pearson’s or Spearman’s coefficients were calculated to study correla-
tions. 
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Studies II and III. Data with non-normal distributions were transformed
into their natural logarithms or square roots. Univariate Pearson’s correla-
tion coefficients and multivariate linear regression analyses were per-
formed separately for the type 2 diabetic and nondiabetic groups. Angio-
graphic indices as dependent variables, independent variables for each
multivariate model were selected from a large number of potential predic-
tor variables such as demographic characteristics and various lipoprotein
and other metabolic data. 
Study IV. Comparisons between the matched groups were performed
using Wilcoxon’s signed rank test for continuous variables and conditional
logistic regression analysis for categorical variables. Comparisons
between  women and men were carried out with unpaired t-tests or Mann-
Whitney rank-sum tests for continuous variables, and chi-square or
Fisher’s exact test for categorical variables. Univariate Spearman’s corre-
lation coefficients (ρ) were calculated to assess associations between
variables separately in the diabetic and nondiabetic groups.
Study V. Spearman’s correlation coefficients (ρ) were calculated to assess
associations between continuous risk variables and angiographic indices.
Categorical risk variables and angiographic indices were studied with the
Mann-Whitney rank-sum test. Characteristics of the female and male, and
DM/IGT and NGT were compared, with ANOVA or Student’s t-test for con-
tinuous variables and chi-square or Fisher’s exact tests for categorical
variables. 
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6. RESULTS
6.1. INTRAOBSERVER VARIABILITY OF QCA ANALYSIS 
QCA analysis intraobserver variability was tested in Study I. The coeffi-
cient of repeatability for the global severity index was 2.5 percentage
points, which means that 95% of the differences between repeat meas-
urements of this index were expected to be less than 2.5 percentage
points. Analytical variability was somewhat larger for global extent and
global atheroma burden indices, as shown by their respective coefficients
of repeatability: 10.3 and 10.8 measurement units.
6.2. SEVERITY AND EXTENT OF CAD BASED ON QCA ANALYSIS 
For consistency, the results that were originally presented as mean ± stan-
dard deviation in Study I are shown here as the median (25th, 75th per-
centile). Also ”PDS index,” used in original Studies I and II, is for the same
reasons replaced with the ”severity index” used in Studies IV and V.
Study I. As shown in Table 4a, 57% of women and over 70% of men in the
type 2 diabetic and nondiabetic groups had 2- or 3-vessel CAD if any
vessel with at least one stenosis ≥ 50% in QCA analysis was taken into
account. When stenoses < 50% were also included, all women and 92%
of diabetic and 96% of nondiabetic men had lesions in their 3 main coro-
nary arteries. Table 4b shows the per-patient number of vessels with at
least one ≥ 70% stenosis.
Table 4a. Patients with significant 0-, 1-, 2, and 3-vessel CAD (vessel with stenosis 
≥ 50% in QCA analysis). (Study I).
Number of Female Male
diseased Type 2 DM+ DM- Type 2 DM+ DM-
vessels (N = 7) (N = 7) (N = 48) (N = 48)
0 0 0 1 (2.0%) 1 (2.0%)
1 3 (43%) 3 (43%) 9 (19%) 12 (25%)
2 0 3 (43%) 27 (56%) 21 (44%)
3 4 (57%) 1 (14%) 11 (23%) 14 (29%)
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Table 4b. Patients with severe 0-, 1-, 2, and 3-vessel CAD (vessel with stenosis 
≥ 70% in QCA analysis). (Study I). 
Number of Female Male
diseased Type 2 DM+ DM- Type 2 DM+ DM-
vessels (N = 7) (N = 7) (N = 48) (N = 48)
0 1 (14%) 3 (43%) 15 (31%) 13 (27%)
1 3 (43%) 3 (43%) 21 (44%) 17 (36%)
2 2 (29%) 1 (14%) 12 (25%) 15 (31%)
3 1 (14%) 0 0 3 (6.0%)
When both sexes were analyzed together, the type 2 diabetic and the non-
diabetic groups were similar with respect to all global indices of CAD;
severity was 51 (43, 61) vs. 53 (43, 65), P = NS; extent was 35 (24, 42)
vs. 32 (24, 39), P = NS; and atheroma burden index was 25 (17, 32) vs.
23 (15, 30), respectively; P = NS. The only marginal difference between
type 2 diabetic and the nondiabetic groups was the higher number of
nondiabetic patients with LAD occlusion (P = 0.05). Otherwise, all the seg-
mental analysis were similar between study groups.
In men (N = 48 per group), the median of the atheroma burden index was
51 (43, 58) in the diabetic group and 55 (43, 66) in the nondiabetic
group, P = NS. However, in type 2 diabetic women, as shown in Figure 5,
the median of the atheroma burden index was remarkably higher than in
nondiabetic women but did not reach statistical significance. 
Figure 5. Median of atheroma burden index by gender in type 2 diabetes
(Study I). Data not shown in the original publication.
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Study IV. Among type 1 diabetic women, when compared with the nondia-
betic control subjects, fewer patients had normal or insignificantly dis-
eased coronary vessels (with no stenosis of ≥ 50%), and more subjects
had 2- or 3-vessel disease, as shown in Table 5a. In fact, as many as 50%
of the nondiabetic women were free of hemodynamically significant
stenoses, compared with 21% of the type 1 diabetic women. Of the type 1
diabetic men, 68% had 2- or 3-vessel CAD compared to 50% of the nondi-
abetic men (Table 5a). Taking into account all stenoses of any severity, 4%
of the type 1 diabetic and 17% of nondiabetic women, and 3% of type 1
diabetic and 5% of nondiabetic men had no detectable coronary artery
stenoses as defined here. As shown in Table 5b, the proportion of dia-
betic women (21%) with at least one stenosis ≥ 70% in at least 2 vessels
approached that seen in men in the same study.
Table 5a. Patients with significant 0-, 1-, 2, and 3-vessel CAD (vessel with stenosis
≥ 50% in QCA analysis).  (Study IV).
Number of Female Male
diseased Type 1 DM+ DM- Type 1 DM+ DM-
vessels (N = 24) (N = 24) (N = 40) (N = 40)
0 5 (21%) 12 (50%) 5 (12%) 7 (18%)
1 5 (21%) 8 (33%) 8 (20%) 13 (32%)
2 7 (29%) 2 (8.5%) 17 (43%) 16 (40%)
3 7 (29%) 2 (8.5%) 10 (25%) 4 (10%)
Table 5b. Patients with severe 0-, 1-, 2, and 3-vessel CAD (vessel with stenosis 
≥ 70% in QCA analysis ).  (Study IV). 
Number of Female Male
diseased Type 1 DM+ DM- Type 1 DM+ DM-
vessels (N = 24) (N = 24) (N = 40) (N = 40)
0 11 (46%) 20 (83%) 11 (28%) 15 (38%)
1 8 (33%) 4 (17%) 20 (50%) 17 (42%)
2 5 (21%) 0 7 (18%) 7 (18%)
3 0 0 2 (4.0%) 1 (2.0%)
47
Type 1 diabetic patients, compared with nondiabetic control subjects, had
significantly more severe and extensive CAD: a global severity index of 49
(37, 62) vs. 34 (16, 52), P < 0.001, a global extent index of 35 (20, 44) vs.
18 (5, 28), P < 0.001, and a global atheroma burden index of 21 (12, 34)
vs. 13 (3, 22), respectively; P < 0.001. 
Figure 6 shows that among women these differences were highly statisti-
cally significant (P < 0.001 for all global indices). Men showed no signifi-
cant difference in global severity, but their CAD was more extensive, and
global atheroma burden was borderline greater in diabetic than in nondi-
abetic men.
Figure 6. Median of atheroma burden index by gender in type 1 diabetes
(Study IV).
Study V. This study population of high-risk subjects, based on their lack of
symptoms, mainly represented mild and early stages of CAD. Men had
more severe and extensive CAD than did women: a median atheroma
burden index of 7.0 (4.0, 12) vs. 3.4 (0.9, 5.7), P < 0.05. 
The 4 subjects receiving antidiabetic medication had a higher median
atheroma burden index than those 47 who did not at 16 (7.0, 19) vs. 5.0
(1.7, 8.9), P = 0.068. However, no significant difference appeared
between the DM/IGT group and the nondiabetic group in median
atheroma burden index, the values being  4.9 (3.8, 13) vs. 5.8 (1.1, 9.0),
P = NS.
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6.3. CORRELATIONS BETWEEN ANGIOGRAPHIC SCORES AND
RISK VARIABLES
6.3.1. Age and known duration of CAD
In type 2 diabetes (Study II), age was a significant predictor of global
severity (P < 0.05) and atheroma burden (P < 0.05) indices, as well as
proximal-segment extent and atheroma burden indices, both in uni- and
multivariate analyses. 
In the type 1 diabetic patients, known duration of CAD was related to global
severity of CAD (Study IV). Age correlated with all global indices (P < 0.05) in
type 1 diabetic women and nondiabetic men, but not in type 1 diabetic men
or nondiabetic women. In Study V, in members of the high-risk families, age
was a predictor of atheroma burden index in women (P < 0.05). 
In the nondiabetic patients in Study II, one of the strongest predictors of
CAD severity was duration of clinically evident CAD.
6.3.2. Lipids
6.3.2.1. Diabetic subjects
.... the good ones in diabetic subjects
In the type 2 diabetic group (Study II), an inverse relation (P < 0.05)
appeared between global atheroma burden and LpA-I levels in proximal
segments in univariate analyses. In a multivariate linear regression
model, the global atheroma burden index was inversely related to LpA-I
levels (P = 0.022). HDL2 cholesterol was a strong negative predictor of
proximal atheroma burden (P < 0.001). 
In the type 1 diabetic group (Study IV), an inverse correlation existed
between HDL cholesterol concentration and global atheroma-burden
index (P < 0.01), mid-segment severity, and atheroma-burden indices,
proximal-segment extent, and atheroma-burden indices (for all, P < 0.05).
.... the bad ones in diabetic subjects
As in the univariate analyses, a multivariate linear regression model
within the type 2 diabetic group (Study II) showed a weak association
between global atheroma burden index and IDL cholesterol concentra-
tions (P = 0.055). In subsegmental analyses, VLDL triglyceride levels were
related to the proximal severity index (P = 0.036), IDL triglyceride levels to
the proximal extent index (P = 0.032), and apoB concentrations to the
distal extent index (P = 0.045). 
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In the type 1 diabetic group (Study IV), serum total cholesterol and triglyc-
eride concentrations failed to correlate with angiographic scores.
6.3.2.2. Nondiabetic subjects
.... the good ones in nondiabetic subjects
In the nondiabetic patients (Study II) univariate analysis revealed apoA-I con-
centration to be the strongest negative predictor of CAD (extent, P < 0.05;
atheroma burden, P < 0.05). Likewise, in the best multivariate model, apoA-I
concentration was the strongest independent inverse predictor of global
atheroma burden (P = 0.008). 
The anti-atherogenic properties of HDL were evident also in the nondia-
betic group of Study IV. A consistent significant inverse relation between
HDL cholesterol and angiographic scores appeared in all 15 segments
and vessel territories analyzed. In the subsegmental analyses, inverse
associations with HDL apolipoproteins occurred only in proximal coronary
segments (apoA-I and severity; apoA-II and severity, P < 0.01 for both)
(Study IV).
.... the bad ones in nondiabetic subjects
In univariate correlation analyses in the nondiabetic patients (Study II),
LDL cholesterol concentration was a significant predictor of global sever-
ity (P < 0.05), extent (P < 0.05), and atheroma burden (P < 0.01) indices.
Furthermore, LDL cholesterol was the most significant pro-atherogenic
predictor also in the multivariate model (P = 0.013). 
In subsegmental analyses, positive associations between coronary scores
and atherogenic lipoproteins were confined to the mid-segments. VLDL
triglyceride levels were related to the proximal severity index (P = 0.036),
IDL triglyceride levels to the proximal extent index (P = 0.032), and apoB
concentrations to the distal extent (P = 0.045).
In Study V, in both sexes and regardless of diabetic status, no significant
correlations appeared between indicators of serum lipid metabolism and
angiographic scores. A trend towards a relation between VLDL cholesterol
and total triglyceride concentrations and the angiographic indices was
evident in women. 
6.3.3. Hyperglycemia and the known duration of diabetes
In type 2 diabetic patients (Study II), known duration of diabetes predicted
global and mid- and distal segment severity of CAD. Glycemic control
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(HbA1c) associated particularly with mid-segment atheroscerosis. In type
1 diabetic subjects (Study IV), known duration of diabetes, but not HbA1c
level, was a consistent predictor of CAD severity and extent globally and in
the mid- and distal segments, but not in the proximal segments. 
The atheroma burden index correlated significantly with fasting blood glu-
cose level in the entire study group in all high-risk subjects in Study V
(ρ = 0.30, P < 0.05), and within the DM/IGT group (ρ = 0.57, P < 0.05). 
6.3.4. Smoking
Cigarette smoking was associated with angiographic indices in type 2 dia-
betic patients (Study II), but this association was absent from the type 1
diabetic population of Study IV.
In Study II in nondiabetic subjects, present or previous smoking was
related to higher angiographic scores. Likewise, in the nondiabetic group
in Study IV, current or former smokers had significantly more severe
values of 30 (17, 43) vs. 15 (8, 33), P = 0.014 and more extensive: 34
(20, 49) vs. 24 (5, 32), P = 0.037 proximal-segment CAD than did sub-
jects who had never smoked. 
In members of high-risk families (Study V), years of smoking correlated
significantly with proximal and global atheroma burden, mid-segment and
global extent, and proximal segment severity indices (for all, P < 0.05).
Furthermore, duration (years) of smoking correlated significantly with tHcy
(ρ = 0.43, P < 0.05).
6.3.5. Nephropathy and albuminuria
The type 2 diabetic population had no nephropathic subjects, due to the
exclusion criteria applied in this study.
In Study IV, as expected, patients with serum creatinine value
< 100 µmol/l had milder CAD than did subjects with > 100 µmol/l, both in
diabetic: a global atheroma burden of 15 (8, 31) vs. 24 (18, 35), P = 0.016,
and in nondiabetic groups: 7 (2, 17) vs. 14 (7, 26), respectively; P = 0.033.
In Study V, albuminuria was the strongest predictor of severe and exten-
sive CAD within the DM/IGT group. The atheroma burden index in the 3
albuminuric subjects was 18 (16, 19), compared to 4.4 (2.6, 5.3) in the
19 subjects without albuminuria (P = 0.01). 
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6.3.6. Homocysteine
Homocysteine levels were unavailable for Studies I to IV. In Study V, serum
tHcy levels correlated significantly with atheroma burden index (ρ = 0.29,
P < 0.05).
Figure 7. Bar graph showing median values for atheroma burden index in
homocysteine quartiles: Q1 = range 7.6–11.1 µmol/l, Q2 = range 11.2–12.8
µmol/l, Q3 = range 12.9–13.8 µmol/l, Q4 = range 13.9–25.0 µmol/l. Spearman
correlations between atheroma burden index and homocysteine ρ = 0.291,
P < 0.05.
As shown in Figure 7, tHcy level had a linear graded effect on severity and
extent of CAD. The median of the atheroma burden index was in the top
homocysteine quartile twice as high as in the lowest homocysteine quar-
tile (Figure 7). No differences existed in plasma tHcy levels between
sexes, nor did differences depend on diabetic status (data not shown). 
A significant association appeared in the DM/IGT group between tHcy
concentration and the 2-hour plasma insulin level after an oral glucose
load (P < 0.02). Furthermore, tHcy concentration correlated with FFA
levels in the DM/IGT group (fasting FFA vs. homocysteine; P < 0.02).
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6.4. CHOLESTEROL EFFLUX POTENTIAL 
In Study III, several of the angiographic indices and the efflux potential
were inversely associated in univariate correlation analyses. The com-
bined study population (N = 88), showed a significant inverse correlation
between efflux and global atheroma burden (P < 0.05).
Figure 8. Scatterplots showing correlations between: Panel A: Capacity of
patient plasma to induce cholesterol efflux from cultured Fu5AH rat hepatoma
cells and mid-segment extent index in the type 2 diabetic group, r = – 0.343,
P < 0.02. Panel B: Capacity of patient plasma to induce cholesterol efflux from
cultured Fu5AH rat hepatoma cells and mid-segment atheroma burden index in
the nondiabetic group, r = – 0.418, P < 0.01.
As shown in Figure 8, in the type 2 diabetic group, efflux capacity was
inversely related to mid-segment extent (P < 0.02), and atheroma burden
(P < 0.03) indices. Similarly, in the nondiabetic group, significant inverse
relations between efflux and severity (P < 0.05), extent (P < 0.02), and
atheroma burden (P < 0.01) indices appeared in the mid-segments. There
was a similar but weaker trend for proximal and global extent indices. 
In multivariate analysis in the nondiabetic group, the correlation between
efflux capacity and global atheroma burden was lost when efflux and LpA-
I levels were included in the same model. When apoA-I was removed,
efflux acquired an inverse borderline significance (P = 0.055). 
In the multivariate model in the diabetic group, this association was inde-
pendent of LpA-I levels, suggesting an impaired anti-atherogenic potential
of these LpA-I particles in type 2 diabetic patients.
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6.5. LEFT VENTRICULAR FUNCTION ANALYSES 
In Studies I and IV, the global and regional left ventricular ejection frac-
tions were similar among the type 1 diabetic (Study IV) and type 2
patients (Study I) when these were compared with those of the respective
nondiabetic groups. 
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7. DISCUSSION
7.1. STUDY DESIGNS AND NOMENCLATURE 
This thesis comprises studies including diabetic subjects with types 1 and
2 diabetes, and patients representing prediabetic stages, as well as nor-
moglycemic subjects. 
Prospective Studies I to III included type 2 diabetic patients and also the
retrospective Study IV type 1 diabetic subjects who underwent cardiac
catheterization for symptoms of CAD. These types of case-control studies
have certain limitations; for example, it is possible that the most severely
ill CAD patients may die before undergoing invasive examinations and be
left out of analyses. 
The prospective series of Study V is unique with respect to angiographic
data for asymptomatic subjects in families at high risk for CAD. 
Classification of diabetes and comparison of different studies on diabetic
subjects is hampered by differences in diagnostic criteria for diabetes
mellitus, as discussed in section 2.5. In our studies, WHO criteria (1980
or 1985) were used, and strict attention was paid to correctly classify sub-
jects by representing either type 2 diabetic patients in Studies I to III or
type 1 in Study IV. For this summary, the terms ”IDDM” and ”NIDDM” that
were used in some of the original publications are replaced with the
terms ”type 1” and ”type 2” diabetes. 
7.2. INDICES OF SEVERITY, EXTENT, AND ATHEROMA BURDEN 
To our knowledge, this is the first study to use QCA-based estimates to
quantify the severity and extent of CAD. Our novel severity, extent, and
atheroma burden indices provide a specific per-patient estimate of the
total atheroma burden of the coronary tree and make possible accurate
subsegmental analyses. A special challenge in the development process
of the angiographic indices was to try to take into account the amount of
atherosclerosis in the totally occluded segments presenting the most
severest forms of CAD. However, the method for calculating the indices is
laborious and therefore not suitable for everyday clinical work. Moreover,
the shortcomings of coronary angiography itself limit the value of these 3
indices.
Although QCA analysis is a major step forward compared to visual analy-
sis of the coronary angiograms, currently, the most reliable data on CAD
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severity and extent would be that obtained by IVUS, which enables imag-
ing of the coronary arteries from within the lumen. IVUS can provide
detailed images of the artery and is the only technique currently available
that can enable visualization of coronary plaques. Compared to coronary
angiography, IVUS gives additional information, but is expensive (Berry et
al. 2000) and time-consuming, and may cause complications. These fac-
tors limit its suitability for routine clinical work. Furthermore, IVUS is even
more limited than angiography in comprehensive evaluation of the coro-
nary tree, because the IVUS catheter is unable to slide past not only total
occlusions but also severe stenoses. It seems probable that coronary
angiography will maintain its place as the main clinical tool until new
techniques are technically ready to take its place. 
7.3. DO DIABETIC PATIENTS HAVE MORE SEVERE AND
EXTENSIVE CAD THAN NONDIABETIC SUBJECTS?
7.3.1. Type 1 diabetes
In accordance with earlier data (Crall et al. 1978, Valsania et al. 1991),
our findings (Study IV) showed that symptomatic type 1 diabetic patients
with a clinical indication for coronary angiography had a more severe,
extensive, and distal type of CAD than did nondiabetic patients of the
same age and sex, even when degree of nephropathy is taken into
account.
Valsania et al. (1991), in their retrospective study based on visual analy-
sis of angiograms in type 1 diabetic patients, did not report any gender
difference. In our series, diabetic men had clearly more extensive CAD
than did nondiabetic men, but less difference appeared between the
groups in the severity of CAD. In women, differences in the angiographic
scores throughout the coronary tree were highly significant. Our results
are supported by recent data by Colhoun et al. (2000), who showed that
even after adjustment for risk factors, diabetes remained associated
with much higher elevation in coronary calcification in women with type
1 diabetes compared with the elevation in nondiabetic women than was
evident in comparison of type 1 diabetic and nondiabetic men. Although
we included only patients who underwent coronary angiography for clini-
cally suspected CAD, half the nondiabetic women of Study IV had no sig-
nificant narrowings by QCA (Table 5a), which is to be expected in this
age group. Therefore, the strikingly greater severity and extensiveness of
CAD in our type 1 diabetic women is partly accounted for by the absence
of significant CAD in the control group. However, it is also apparent
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(Table 5a) that among those women who did have significant coronary
narrowings, extensive disease was more prevalent among the type 1 dia-
betic patients.
7.3.2. Type 2 diabetes
Study I showed that symptomatic CAD patients, with and without type 2
diabetes, have a similar severity and extent of CAD. Recent data from the
Diabetes Atherosclerosis Intervention Study support our findings (Dia-
betes Atherosclerosis Intervention Study Investigators 2001). However,
our results may seem to contradict the evidence of more severe and
extensive CAD in the type 2 diabetic population than in nondiabetic sub-
jects, as found in some studies (Vigorita et al. 1980, Waller et al. 1980,
Calton et al. 1995, Natali et al. 2000). Further analysis of current and
previous data may illuminate this problem. 
Patients in Study I were symptomatic for CAD: 57% of women in each
group, and 79% of diabetic and 73% of nondiabetic men had 2- or 3-
vessel CAD. Only 2% of men and none of the women had a totally normal
coronary tree. Of the type 2 diabetic patients in the recent study by Natali
et al. (2000), 15% underwent coronary angiography for reasons other
than CAD. In that study, the percentage of subjects with a completely
normal coronary tree was high, 33% of the nondiabetic patients and 15%
of the diabetic group (Natali et al. 2000). It is worth mentioning that in
Study I the threshold for sending patients for coronary angiography at the
time of the patient collection was high, and no diabetic patient was
excluded by our requirement of one 50% stenosis.
It is important to notice that our type 2 diabetic population included
mainly male and only 7 female pairs. This is due to a surprisingly low
inclusion rate of female patients during the prospective study series col-
lection period between September 1989 and February 1992. The reason
for this remains unknown and raises the question whether the threshold
for invasive examinations has been higher for women than in men.
In our series, there existed a 46% difference in atheroma burden between
diabetic and nondiabetic women that did not reach statistical signifi-
cance; our results remain only suggestive. Data from other studies sup-
port the view that, as seen in our type 1 diabetic series, a gender differ-
ence may exist also in our type 2 patient population. The study by Natali
et al. (2000) that included a 27% proportion of female patients suggests
that type 2 diabetic women have more advanced CAD than do nondia-
betic women with CAD. Similar results has been observed also in a study
by Calton et al. (1995). 
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Hamby et al. (1976) reported a higher coronary score and more 3-vessel
disease in type 2 diabetic and IGT groups than in their nondiabetic group.
This difference was confined to hypertriglyceridemic patients, but, unfor-
tunately, insulin levels were not measured. It is interesting to speculate
whether these results can be explained by differences in insulin resist-
ance rather than in diabetic status. As reported earlier, the groups in
Study I comprised subjects with an equal degree of hyperinsulinemia
(Syvänne et al. 1995).
7.3.3. Prediabetic stages
A recent EBCT study has reported higher coronary artery calcium scores
in a combined group of type 1 and 2 diabetic patients than in nondiabetic
controls, all without symptoms of CAD (Schurgin et al. 2001). In Study V,
asymptomatic subjects with regard to CAD had similar angiographic
scores, with the exception of those four on antidiabetic medication. The
combined IGT/DM group as a whole consisted mainly of milder stages of
diabetes and of newly diagnosed patients. Ledru et al. (2001) have
recently compared the severity and extent of CAD with regard to the new
(ADA 1997) and old (WHO 1980) criteria for diagnosis and classification
of diabetes. They discovered that patients with fasting plasma glucose
between 7.0 and 7.7 mmol/l had a severity and extent of CAD more simi-
lar to those with normal plasma glucose level than to those with plasma
glucose over 7.7 mmol/l or with previously diagnosed diabetes. 
”Prediabetic” patients with IFG and IGT, however, are at increased risk of
death due to CAD (The DECODE study group, 1999a). This may be due to
the fact that most acute coronary events result from thrombosis at sites
of minor plaques that may be more vulnerable in ”prediabetic” patients.
One possibility is, however, that our current techniques may fail to detect
the difference in early stages of atherosclerosis. The coronary angiogram
remains ”normal” until CAD is far advanced (Nissen and Yock 2001), and
despite the aid of QCA analysis software, there are limitations in detection
of early-stage CAD by coronary angiography. 
7.4. WHY ARE WOMEN PARTICULARLY AFFECTED BY A
COMBINATION OF CAD AND DIABETES?
Women before menopause have lower rates of CAD than do men. Nor-
mally, before age 55 their incidence of CAD is one-third that of men, and
the ratio attains unity only at the age of 75 years (Castelli 1984). Dia-
betes obviates this benefit (Kannel and McGee 1979b, Pan et al. 1986,
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Colhoun et al. 2000). It was already evident in the Framingham cohort
that the relative impact of diabetes on cardiovascular mortality and car-
diac failure is greater in women than in men, but the reason is still
unknown (Kannel and McGee 1979b, Abbott et al. 1988). This sex-differ-
ence seems to apply among various ethnic groups (Howard et al. 1998).
It is as yet unknown what generates this gender difference that already
exists in the prediabetic stages with asymptomatic hyperglycemia (Pan et
al. 1986). Diabetic women have slightly more adverse changes in athero-
genic risk factors than do men (Howard et al. 1998). As reviewed by
Sowers (1998), several mechanisms such as pathological effects related
to central obesity, enhanced coagulation and platelet functions, lipopro-
tein abnormalities, and changes in growth factor stimulation have been
suggested. The role of sex hormones is also of interest, because some
positive effects of estradiol may be abrogated by diabetes (Sowers 1998).
In addition, lipid peroxidation has been shown to be increased in type 1
diabetic women but not in men (Evans and Orchard 1994). It has been
suggested that female patients are somehow more prone to the effect of
”family history of CAD” as a risk factor (Pohjola-Sintonen et al. 1998) and
suffer more disadvantages from smoking (Schumacher et al. 1990, Boer
et al. 1999). Lloyd et al. (1996) observed in type 1 diabetic patients in the
Pittsburgh Epidemiology of Diabetes Complications Study that nephropa-
thy predicted the presence of CAD better in men than in women. 
Despite these interesting theories, the reason for the greater impact of
diabetes particularly in pre-menopausal women remains an unsolved
mystery. Before the factors causing this phenomenon are better under-
stood, it is difficult to begin using precise measures for prevention.
7.5. DETERMINANTS OF CAD
7.5.1. Hyperglycemia and duration of diabetes
The recent ”milestone” studies in diabetic research, the UKPDS and The
Diabetes Control and Complications Trial, have provided us with only bor-
derline support for the effect of tight blood glucose regulation in reduction
of macrovascular events (The UKPDS Group 1998, The Diabetes Control
and Complications Trial Research Group 1993). In the UKPDS study
(1998), tight blood glucose regulation reduced microvascular complica-
tions in particular, whereas benefit for the prevention of macrovascular
disease reached only borderline significance. However, recent epidemio-
logical data from the UKPDS 35 study show that in type 2 diabetic sub-
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jects, even a mere 1% reduction in mean HbA1c was associated with sig-
nificant reduction in complications and mortality due to CAD, independ-
ently of conventional risk factors (Stratton et al. 2000). The Diabetes Con-
trol and Complications Trial in type 1 diabetic patients observed that the
benefit of tight glucose control was associated with reduced progression
of microvascular complications. The combined risk for coronary and
peripheral vascular events was reduced by 41%, however, a result not sta-
tistically significant in this young patient population (The Diabetes Control
and Complications Trial Research Group 1993).
As a crude estimate of duration of exposure to hyperglycemia and to
other diabetes-related metabolic disturbances, the known duration of clin-
ically evident diabetes was one of the most consistent risk factors for CAD
severity and extent in the type 2 diabetic group (Study II), just as it was a
consistent predictor of CAD in the middle and distal segments in type 1
diabetic patients (Study IV). In the type 2 diabetic group, glycemic control
(HbA1c) was related to mid-segment angiographic indices (Study II). This
correlation was absent from the type 1 population (Study IV), however,
these clinical data were acquired retrospectively. A single measurement
of HbA1c must be considered an imprecise indicator of long-term expo-
sure to hyperglycemia, and it is thus probable that the association
between hyperglycemia and severity and extent of CAD is stronger than
found in our studies.
The fact that type 2 diabetic patients often present with symptoms of CAD
even at the time of diagnosis is probably related to the presence of insulin
resistance syndrome together with a clustering of risk factors: hyperten-
sion, central obesity, elevated triglycerides, and low HDL cholesterol
(Laakso and Lehto 1998). Type 2 diabetes is preceded by IGT, and the
presence of IGT generates a 2-fold increase in risk for cardiovascular com-
plications (Laakso 2000). Most of the subjects in the IGT/DM group in
Study V could be classified as prediabetic or with newly diagnosed dia-
betes. In this group, the amount of coronary atheroma was predicted by
fasting blood glucose level. Genetic factors also play a role in hyper-
glycemia-induced tissue damage (Brownlee et al. 1988).
Hyperglycemia mediates its adverse effects by several pathways, one of
them glycosylation of proteins. Accumulation of AGEs into the artery wall
causes deleterious metabolic events such as enhanced formation of oxi-
dized LDL (Nakamura et al. 1993). These pathological changes occur
early in diabetic vessels, but oxidative stress is aggravated by insulin
resistance also in normoglycemic subjects (Paolisso and Giugliano 1996). 
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7.5.2. Lipids – the good ones and and the role of cholesterol
efflux 
The well-established antiatherogenic role of HDL and related particles
was observed both in the type 1 and type 2 diabetes groups and in the
nondiabetic groups in Studies II and IV. In line with earlier data (Host-
mark et al. 1990), among the nondiabetic subjects in Study II, apoA-I
concentration was a protective factor against global severity and extent
of CAD.
In Study III we showed that severity and extent of CAD is related to in vitro
cholesterol efflux from Fu5AH cells. In multivariate analysis for the nondi-
abetic group, the correlation between efflux capacity and global atheroma
burden was lost when efflux and LpA-I levels were included in the same
model, but when apoA-I was removed, efflux acquired an inverse border-
line significance. This implies that in the cholesterol efflux process, apoA-I
is an important mediator.
Our data provide novel insights into the impaired function of RCT in type 2
diabetic men. In Study III, the weaker antiatherogenic role of LpA-I parti-
cles in diabetic compared with nondiabetic subjects implies that LpA-I
particles do not function properly in type 2 diabetic men with CAD. 
The mechanisms affecting the deterioration of RCT in type 2 diabetic
patients are unknown. In such patients, the enrichment of HDL with
triglycerides may be one important factor behind their impaired RCT. In a
recent study by Autran et al. (2000), bezafibrate treatment restored the
impaired fasting efflux function, but the postprandial RCT, which was 28%
lower than in controls, was only somewhat improved. 
It is also of interest to consider the function of cell membrane proteins.
Variation in ABCA1 is significantly associated with plasma lipid levels and
with the severity of CAD in the general population. Mutations within the
ABCA1 gene have been related to lower HDL cholesterol and higher
triglyceride levels and to a greater than 3-fold increase in frequency of
CAD (Clee et al. 2000 and 2001). The role of ABCA1 in diabetic patients
is not established. 
Studies concerning glycosylation of HDL and cholesterol efflux are some-
what contradictory (Igau et al. 1997, Rashduni et al. 1999). One interest-
ing link between diabetes and cholesterol efflux is glycosylation of pro-
teins. Recent data indicate that AGEs as ligands for cell membrane pro-
tein SR-B1 effectively inhibit both SR-B1-mediated selective uptake of
HDL and cholesterol efflux from peripheral cells to HDL, suggesting that
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AGEs may play a role in SR-B1-mediated cholesterol metabolism in vivo
(Ohgami et al. 2001). Modulation of the activity of cell membrane pro-
teins may in the future provide the basis for treatment and prevention of
CAD.
7.5.3. Lipids – the bad ones
In the type 2 diabetes group (Study II), rather weak correlations existed
between measures of CAD and levels of lipids. This was also true for other
”classic” risk factors for CAD such as hypertension and smoking. 
This finding does not constitute evidence against the atherogenicity of
these particles. On the contrary, LDL particles in diabetic patients are
small and dense, and therefore highly atherogenic even at low levels, due
to their interaction with TRLs (Syvänne and Taskinen 1997). The quality of
LDL particles seems to be a more important determinant than the
absolute concentration of LDL cholesterol, explaining the lack of direct
association between angiographic severity of CAD and LDL cholesterol in
the type 2 diabetes subjects in Study II. In that group, some of the angio-
graphic indices were directly associated with variables describing levels of
TRLs. Similar findings between CAD severity scores and TRLs have been
observed also in men < 45 years after they suffer MI (Törnvall et al.
1993). Brites et al. (2000) have shown that in hypertriglyceridemic men
the capacity of serum samples to promote cellular cholesterol efflux is
reduced. Thus, abnormalities in the cholesterol efflux and its promoters
may constitute a possible connection between hypertriglyceridemia and
atherosclerosis.
LDL cholesterol concentration is often nearly normal in type 1 diabetes
(Orchard et al. 1999). In agreement with this, Study IV showed in the type
1 diabetes group that serum cholesterol and triglyceride concentrations
were subnormal and unrelated to angiographic indices. Oxidation of LDL
may play a role in the development of CAD. Recently, antibodies to oxi-
dized LDL and LDL-containing immune complexes, rather than LDL con-
centration, were found to be predictors of CAD in type 1 diabetes (Orchard
et al. 1999). As in the diabetic group, an association between LDL and
CAD was absent from the nondiabetic group of Study IV, but, as expected,
was present in the nondiabetic group of Study II. It should be noted that
clinical data in Study IV were retrieved retrospectively from medical
records. However, the absence of this association in Study IV may be
related to the fact that the nondiabetic study group also included sub-
jects with abnormal kidney function, a fact that may have affected the
results. 
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High LDL and low HDL cholesterol levels have been shown to predict
angiographic CAD severity in high-risk subjects (Sharp et al. 1992). Unex-
pectedly, no significant correlations existed between numerous indicators
of serum lipid metabolism and the angiographic scores in Study V. This
finding may be explained by the confounding effect of the use of antilipid
medications. 
7.5.4. Homocysteine
Studies concerning the role of hyperhomocysteinemia in patients with
premature CAD are in part contradictory. Nikfardjam et al. (2001) found
no relation between tHcy levels and the anatomical extent of CAD in
patients with symptomatic premature CAD. Kawashiri et al. (1999)
reported plasma tHcy levels to predict significantly the age of onset of
CAD; mild hyperhomocysteinemia was associated with the risk for CAD
and was found to be highly prevalent in offspring of such patients (Pinto
et al. 2001). De Jong et al. (1997) observed that healthy siblings of
patients with premature atherosclerosis have a high prevalence of hyper-
homocysteinemia and asymptomatic vascular disease. Our data fall in
line with these observations by showing that tHcy levels had a linear
graded effect on severity and extent of CAD in asymptomatic members of
high-risk families that were siblings of patients with early-onset severe
CAD (Study V).
Would there exist a link between homocysteine and the metabolic syn-
drome? In contrast to a report by Bar-On et al. (2000), we found in Study
V a significant association between plasma homocysteine concentration
and 2-hour plasma insulin level in diabetic and IGT groups. Hyperhomo-
cysteinemia was also associated with hyperinsulinemia in the Framing-
ham Offspring study (Meigs et al. 2001), and tHcy correlated with insulin
sensitivity indices and nephropathy in type 2 diabetic patients (Emoto et
al. 2001). Unfortunately, in our series we did not examine the relation
between angiographic indices and homocysteine levels in type 1 or 2 dia-
betes. Hoogeveen et al. (1998 and 2000) have suggested that the hyper-
homocysteinemia might contribute to the accelerated atherosclerotic
process, especially in type 2 diabetic populations. 
Several ongoing clinical trials hope to answer the question: Should hyper-
homocysteinemia be treated? (Glenn and Duell 1999). Although suspi-
cions exist that homocysteine might be more an indicator of the global
cardiovascular risk than an independent risk factor, some data support its
clinical value. Plasma tHcy levels have been shown to predict mortality in
patients with angiographically confirmed CAD (Nygård et al. 1997) and
long-term survival after MI (Omland et al. 2000, Stubbs et al. 2000).
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Recently, Vermeulen and coworkers (2000) discovered that healthy sib-
lings of patients with premature CAD benefit from treatment with folic
acid and vitamin B6. This simple treatment reduced the occurrence of an
abnormal exercise test in a study that comprised 158 healthy subjects
(Vermeulen et al. 2000). Folic acid supplementation has also been shown
significantly to improve endothelial dysfunction in patients with coronary
atherosclerosis (Title et al. 2000). A recent prospective, double-blind, and
randomized trial with a combination treatment of folic acid, B6 vitamin,
and pyridoxine observed decreased need for revascularization after coro-
nary angioplasty and reduced tHcy levels (Schnyder et al. 2001).
7.5.5. Smoking
In an angiographic study by Wilson et al. (1999b), current or former smok-
ing was associated with CAD severity and extent scores in subjects
coming to elective coronary angiography. In agreement with that and
other earlier studies, smoking was strongly related to severity and extent
of CAD in the nondiabetic groups of Studies II and IV. As expected, smok-
ing correlated significantly with tHcy (Study V), an association observed
also in large-scale epidemiological studies, as reviewed recently by Nygård
et al. (1999).
Surprisingly, angiographic scores showed no correlation with history of
smoking, neither in the type 1 diabetic group that included a remarkably
high proportion of subjects who were current or former smokers (Study IV)
nor in type 2 diabetic subjects (Study II). This was also true for other ”clas-
sic” risk factors of CAD, such as hypertension in Study II. One mechanism
underlying the absence of these associations might be that in the statisti-
cal analyses more powerful diabetes-related factors submerge the classi-
cal factors. 
7.6. CAD AS A MULTIFACTORIAL PROCESS 
Any evaluation of the importance of different determinants of CAD is com-
plicated by the fact that development of CAD is a highly multifactorial
process, and many of the participating factors are interrelated. As Kruth
(1997) has stated, ”There may be as many factors as there are scientists
working on the question.” It is also possible that different risk factors
account – to varying degrees – for the development of CAD, depending on
disease stage and interactions between variables. Determinants may also
show a differing influence on different parts of the coronary tree, as indi-
cated by Study II. With the escalating number of known risk factors, it is
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not likely that we can control for all the important determinants in the
statistical models. 
Novel and yet unknown determinants, as well as some of ”the old ones,”
may have means of action or interrelations beyond our current knowl-
edge. Recent population-based data from the National Health and Nutri-
tion Survey reported by Frohlich et al. (2000), as well as The Insulin Resis-
tance Atherosclerosis Study (Festa et al. 2000), suggest, however, and
not unexpectedly, a correlation between a variety of features of the meta-
bolic syndrome and markers of inflammation. As recently reviewed by
DeLoughery (1999), one interesting new role and pathway of action for
lipoproteins may be their ability to control coagulation through influencing
the presence of phospholipid surfaces needed for coagulation reactions.
Factors related to the presence of CAD do not necessarily predict its
severity. Hoffmeister et al. (2001) studied markers of inflammation and
the severity of CAD. Although all markers were highly significantly elevated
in patients with stable CAD (but not in controls), no association appeared
between such markers and measures of CAD severity. Furthermore,
lifestyle factors that might have an impact on atherosclerosis differ
between countries. 
7.7. LEFT VENTRICULAR FUNCTION ANALYSES 
In the present study, the left ventricular function both in Studies IV and I
was similar between the diabetic and nondiabetic groups. This is in line
with earlier findings. Patients who have subclinical diabetic cardiomyopa-
thy and diastolic dysfunction, even though they have a quite normal ejec-
tion fraction, may develop clinical heart failure (Aronson et al. 1997,
Timmis 2001). Although diabetic subjects may have systolic function simi-
lar to that of nondiabetic subjects, they show twice the incidence of pul-
monary edema after acute MI (Granger et al. 1993), and their excess in-
hospital mortality is caused mainly by congestive heart failure, as
reviewed by Aronson et al. (1997). 
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8. SUMMARY AND CONCLUSIONS
1. The severity and extent of CAD was similar in type 2 diabetic patients
and in nondiabetic subjects matched for sex, age, and body mass
index. This finding is limited to patients that become symptomatic and
need angiographic assessment at similar ages, and may be affected
by the inclusion criteria that required participants to have at least one
> 50% occlusion in visual analysis of their angiograms. Our consecu-
tive series of type 2 diabetic patients consisted predominantly of men.
Further research is needed to evaluate the severity and extent of CAD
in type 2 diabetic women.
2. Between type 2 diabetic patients and nondiabetic subjects, the deter-
minants of the angiographic severity and extent of CAD differed. In
nondiabetic subjects, the angiographic measures of CAD were associ-
ated with ”traditional” risk factors such as smoking, hypertension, and
LDL cholesterol. These correlations were replaced with diabetes-
related variables. Even normal levels of apolipoprotein B-containing
particles are atherogenic when diabetes is present.
3. In vitro cholesterol efflux capacity was inversely associated with sever-
ity and extent of CAD in men with type 2 diabetes and in nondiabetic
subjects. In the diabetic group, this association was independent of
LpA-I levels, suggesting that in type 2 diabetic patients with CAD, the
antiatherogenic potential of LpA-I particles is diminished. 
4. Type 1 diabetic patients, particularly women, had a more severe,
extensive, and distal type of CAD than did individually matched control
patients. The greater impact of type 1 diabetes in women is not
explained by the known risk factors. This may be related to diabetes-
related defects in mechanisms by which pre-menopausal women are
usually protected against CAD. 
5. The serum homocysteine and glucose levels were associated with the
severity and extent of CAD in asymptomatic but high-risk subjects with
a positive family history of CAD. 
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